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1. Introduction
The T cell response to influenza virus infection is di-
rected at processed viral peptides that are presented on 
the surface of APCs in the context of MHC class I and 
class II molecules [1, 2]. While substantial progress has 
been made in understanding the mechanisms involved 
in the acquisition and processing of viral proteins into 
peptides, less is known about the number of epitopes 
involved in a T cell response. The best understood sys-
tem is the class I-restricted CD8+ T cell response to influ-
enza virus infection in inbred mice. For example, 16 H-
2Kb and H-2Db-restricted epitopes have been identified 
in C57BL/6 mice following influenza virus infection and 
these epitopes have provided insight into the breadth of 
the T cell response and patterns of immunodominance 
[3–8]. In addition, these epitopes have provided a basis 
for mechanistic and vaccine studies, and reagent devel-
opment, including MHC-peptide tetramers. In stark con-
trast, much less is known about the class II-restricted 
CD4+ T cell response in C57BL/6 mice, with only two 
putative I-Ab-restricted epitopes identified in the in-
fluenza x31 virus [9, 10]. The comparative lack of infor-
mation on the CD4+ T cell response partially reflects the 
difficulties in identifying potential class II-restricted epi-
topes. In general, peptide binding to MHC class II mole-
cules is less stringent than for peptide binding to MHC 
class I molecules. Thus, it has been correspondingly dif-
ficult to develop algorithms to predict potential class II-
restricted epitopes [11, 12]. One of the more recently de-
veloped algorithms, RANKPEP, allows for the input of 
protein sequences and then determines the rank and per-
centile optimal binding of the predicted class II epitope 
[11, 12]. However, it is still unknown whether this al-
gorithm can accurately predict class II epitopes in most 
proteins.
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The identification of T cell epitopes is crucial for the understanding of the host immune response during infection. While much 
is known about the MHC class I-restricted response following influenza virus infection of C57BL/6 mice, with over 16 CD8 epit-
opes identified to date, less is known about the MHC class II-restricted response. Currently, only a few I-Ab-restricted T helper ep-
itopes have been identified. Therefore, several important questions remain about how many class II epitopes exist in this system 
and whether these epitopes are evenly distributed within the most abundant viral proteins. In order to address these questions, 
we analyzed the repertoire of epitopes that drive the CD4+ T cell response to influenza virus infection in C57BL/6 (H-2b) mice. Us-
ing a panel of overlapping peptides from each of the viral proteins we show that approximately 20–30 epitopes drive the CD4 T 
cell response and that the majority of these peptides are derived from the NP and HA proteins. We were also able to demonstrate 
that vaccination with one of the newly identified epitopes, HA211–225/A
b, resulted in increased epitope-specific T cell numbers and 
a significant reduction in viral titers following influenza virus challenge.
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Because of the lack of detailed information on class II-
restricted epitopes in the murine influenza virus model, 
many questions remain unanswered regarding the spec-
ificity and diversity of the CD4+ T cell response. For ex-
ample, it is believed that the CD4+ T cell response is much 
more diverse than the CD8+ T cell response in terms of 
the number of epitopes recognized; however, there is no 
direct evidence for this supposition. In addition, it is not 
known whether CD4+ T cell epitopes are evenly distrib-
uted within specific viral proteins, although there is some 
evidence that they may be enriched in regions of pro-
teins that are recognized by antibodies [13, 14]. There is 
also little information on the capacity of CD4+ T cell epi-
topes to mediate effective antiviral immunity in the con-
text of peptide-based vaccines. Clearly, there is a need to 
develop a better understanding of the numbers and dis-
tribution of MHC class II-restricted epitopes in the influ-
enza virus.
Here we analyzed the breadth of the CD4+  T  cell  re-
sponse to influenza virus in C57BL/6 mice using a panel 
of peptides derived from all the major proteins of the x31 
strain of influenza virus and compared the epitopes iden-
tified by functional studies with those predicted by the 
RANKPEP algorithm. We demonstrate that CD4+  T  cell 
epitopes are unevenly distributed in a limited number 
of proteins and estimate the total number of distinct epi-
topes to be in the range of 20–30, most of which were not 
predicted by the RANKPEP program. Two of these epi-
topes appear to be immunodominant inasmuch as they 
drive a major fraction of the CD4+ T cell response to acute 
influenza virus infection. Additionally, we found that 
vaccination with one of these CD4 epitopes resulted in 
an enhanced CD4+ T cell response and a significant de-
crease in viral loads following a subsequent influenza vi-
rus challenge.
2. Materials and methods
2.1. Generation of influenza peptides and epitope prediction
Amino acid sequences were obtained from PubMed 
for the proteins of the A/HK-x31 (x31, H3N2) and A/
PR8/34 (PR8, H1N1) strains of the influenza virus. Ly-
ophilized non-amidated peptides, 15 mers overlapping 
by 10, were generated and purchased from New England 
Peptide (Gardner, MA) and solubilized with a 50:50 ace-
tonitrile/H2O solution. To avoid multiple freeze/thaw 
cycles, the peptides were then diluted to a concentration 
of 0.5 μg/ml with Hank’s Balance Salt Solution and ali-
quoted into round bottom 96 well plates. Potential T cell 
epitopes (MHC II—I-Ab) were predicted using the matrix-
based algorithm RANKPEP [11, 12].
2.2. Viruses, animals, and infections
The reassortant influenza virus strain A/HK-x31 (x31, 
H3N2 = A/Hong Kong/1/68 × A/Puerto Rico/8/34) 
was grown, stored and titrated as previously described 
[15]. Female C57BL/6 mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). Mice (6–12 weeks) were 
anesthetized by i.p. injection with 2,2,2 tribromoethanol 
and infected intranasally with 300 or 600 50% egg infec-
tious doses (EID50) of influenza virus.
2.3. Enzyme-linked immunospot assay (ELISpot)
The numbers of IFNγ-secreting cells derived from 
spleens of infected mice were determined after stimula-
tion with influenza peptides in a standard enzyme-linked 
immunospot (ELISpot) assay [16]. Briefly, 96 well Multi-
screen mixed ester nitrocellulose plates (Millipore, Bed-
ford, MA) were coated overnight at 4 °C with 100 μl well 
of rat anti-mouse IFNγ (B-D Pharmingen, San Jose, CA) at 
a concentration of 10 μg/ml. The plates were then washed 
and blocked before the addition of 105 responding cells, 
irradiated (3000 rad) syngeneic normal spleen cells, 
10 μg/ml peptide, and 40 U/ml IL-2. Plates were then in-
cubated 48 h at 37 °C and developed overnight with a bi-
ontinylated detection antibody, rat anti-mouse IFNγ (B-D 
Pharmingen, San Jose, CA). The plates were then incu-
bated with streptavidin-alkaline phosphatase (DakoCyto-
mation, Carpinteria, CA) for 1 h, washed, and incubated 
with BCIP/NBT alkaline phosphatase substrate (Sigma, 
St. Louis, MO) for 2 h at room temperature. Visible spots 
of IFNγ secreting cells were then enumerated using an 
Olympus SZH stereo zoom microscope system.
2.4. Intracellular cytokine staining
Lymphocytes were collected from the spleens or lung 
airways (broncoalveloar lavage) as previously described 
[17]. Following collection, the cells were washed and de-
pleted of erythrocytes. Isolated cells (106cells/condition) 
were cultured at 37 °C for 5 h in the presence of 10 μg of 
the indicated peptide in 250 μl of complete tumor me-
dium (CTM) containing 10 μg/ml Brefeldin A (BFA; Epi-
center Technologies, Madison, WI) and 10 U/ml IL-2 
(R&D Systems, Minneapolis, MN) [18]. After culture, the 
cells were blocked with monoclonal antibodies to FcRIII/
II receptor (B-D Pharmingen, San Jose, CA) and stained 
with anti-CD4 conjugated to FITC anti-CD8 conjugated 
to PerCP, and anti-CD44 conjugated to allophycocyanin 
antibodies (B-D Pharmingen, San Jose, CA) in PBS/BFA. 
The cells were then fixed in 2% formaldehyde, permea-
bilized with buffer containing 0.5% saponin, and stained 
with anti-IFNγ conjugated to PE (B-D Pharmingen, San 
Jose, CA) monoclonal antibody. 200,000 events were col-
lected on a Becton Dickinson FACSCalibur flow cytome-
ter. Data was analyzed using FlowJo (TreeStar) software.
2.5. Generation of LacZ-inducible T cell hybridomas
Splenocytes were harvested from C57BL/6 mice 28 
days after intranasal challenge with A/HKx31. 30 × 106 
immune splenocytes were cultured with 30 × 106 irra-
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diated (3000 rad) peptide pulsed (2 μg/ml specific pep-
tide) syngeneic splenocytes for 5 days. Blast cells were en-
riched by Ficoll and then fused with BWZ.36 cells [19, 20]. 
The resulting clones were tested for specificity using pep-
tide-pulsed L cells transfected with the I-Ab MHC genes.
2.6. Antigen presentation assays
Antigen presentation assays were performed as pre-
viously described [20–24]. Briefly, hybridomas (1 × 105) 
were cultured with virus-infected or peptide-pulsed cells 
in flat-bottomed microtiter plates. The plates were incu-
bated overnight, washed with PBS and fixed with β-ga-
lactosidase fixative (2% formaldehyde/0.2% glutaralde-
hyde). Cells were washed again with PBS followed by the 
addition of 50 μl of a 1 mg/ml X-gal solution (5 mM po-
tassium ferrocyanide, 5 mM potassium ferricyanide, and 
2 mM magnesium chloride). After 4 h, the hybridomas 
were examined under a light microscope for the presence 
of blue cells.
2.7. Bone marrow derived dendritic cells and vaccination
Bone marrow was flushed from the femurs of C57BL/
6 mice, depleted of erythrocytes, and 2 × 106 mononuclear 
cells were placed into a bacteriological Petri dish with 
media supplemented with 20 ng/ml recombinant mu-
rine granulocyte/macrophage colony-stimulating factor 
(rmGM-CSF; Peprotech, Rocky Hill, NJ) and incubated at 
37 °C with 10% CO2 [25]. On day 3, an additional 10 ml 
of CTM containing 20 ng/ml rmGM-CSF was added. On 
day 6, half of the cells were removed, centrifuged, and 
added back to the same plate in 10 ml of fresh media con-
taining 20 ng/ml rmGM-CSF. On day 8 the cells were re-
moved, centrifuged, and 2 × 106 cells were placed into 
new bacteriological Petri dishes in 10 ml of media supple-
mented with 20 ng/ml rmGM-CSF. On day 10 of the cul-
ture, the cells were resuspended at 5 × 106/ml and incu-
bated at 37 °C for 3 h with peptide at a concentration of 
50 μg/ml [18]. Following peptide pulsing, the dendritic 
cells were washed and 100 μl of cells in PBS were injected 
i.v. into mice at a final concentration of 1 × 106 cells  per 
mouse [18]. Three weeks post dendritic cell vaccination, 
the mice were injected subcutaneously with 100 μg of 
peptide emulsified in incomplete Freud’s adjuvant [26].
2.8. Viral titers
Homogenized lungs were serially diluted and injected 
into three 10 day old embryonated hen eggs per sample. 
After incubation at 35 °C for 48 h, allantoic fluid from 
each egg was sampled and assayed for hemagglutinating 
activity using chicken red blood cells as previously de-
scribed [27]. Samples were scored as positive when two of 
the three eggs contained hemagglutinating activity [27].
3. Results
3.1. Primary screen for T cell epitopes within influenza virus 
proteins
To identify MHC class II-restricted epitopes from in-
fluenza virus, we synthesized a panel of 15-mer peptides 
(overlapping by 10 amino acids) from each of the pub-
lished x31 influenza virus protein sequences and from the 
PR8 influenza virus hemagglutinin (HA) and neuramini-
dase (NA) protein sequences (Table 1). Altogether, a total 
of 1085 peptides were synthesized and are listed in Sup-
plemental Tables 1 and 2. These peptides were then used 
to screen splenocytes from mice that had recovered from 
a prior intranasal x31 infection (21 days post-infection) in 
two independent ELISpot assays. As shown in Figure 1 
and Figure 2, many of the peptides elicited ELISpot re-
sponses that were above three standard deviations of 
the background (i.e. more than 10 spots). The majority of 
these positive responses were elicited by peptides derived 
from the HA, nucleoprotein (NP), acidic polymerase (PA) 
and basic polymerase (PB1 and PB2) proteins of x31 (Fig-
ure 1). Relatively few positive responses were elicited by 
peptides derived from the NA, nonstructural (NS1 and 
Table 1. Influenza virus proteins
Protein                                                                      Accession number (PubMed)                  Sizea            Number of peptides
Hemagglutinin x31 (HA) PO 3437 566 112
Hemagglutinin PR8 (HA) AAM 75158 565 112
Neuramidase x31 (NA) BAC 77663 469 93
Neuramidase PR8 (NA) NP 775534 454 90
Nucleoprotein (NP) BAA 99400 498 99
Acidic polymerase (PA) BAA 99401 716 142
PB1 polymerase (PB1) BAA 99402 759 151
PB2 polymerase (PB2) BAA 99403 757 151
Non-structural 1 (NS1) BAA 99396 230 45
Non-structural 2 (NS2) BAA 99396 121 23
Matrix protein 1 (M1) BAA 99399 252 49
Matrix protein 2 (M2) BAA 99398 97 18
a Amino acids.
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Figure 1. Infection induces T cells specific for peptides within the hemagglutinin, nucleoprotein protein, acidic polymerase, ba-
sic polymerase 1, and basic polymerase 2 of the x31 influenza virus. C57BL/6 mice were intranasally infected with 300 EID50 x31 
influenza virus. On day 21 post infection the spleens were removed, enriched for lymphocytes, and incubated for 48 h with ir-
radiated (3000 rad) syngeneic normal spleen cells, peptide, and IL-2 in a standard IFNγ specific ELISpot assay. Shown are the 
number of IFNγ positive cells from one of two representative experiments following incubation with peptides from the follow-
ing proteins: HA derived from x31, HA derived from PR8, NP, PA, PB1, and PB2 (all derived from x31). Blue bars indicate the re-
gions containing the known CD8 epitopes and yellow bars indicate the region containing the known CD4 epitope.
Figure 2. Infection does not induce T cells specific for peptides within the neuramidase, maxtrix 1, matrix 2, nonstructural 1, and 
nonstructural 2 proteins of the x31 influenza virus. C57BL/6 mice were intranasally infected with 300 EID50 x31 influenza virus. 
On day 21 post infection the spleens were removed, enriched for lymphocytes, incubated for 48 h with irradiated (3000 rad) syn-
geneic normal spleen cells, peptide, and IL-2 in a standard ELISpot assay. Shown are the number of IFNγ positive cells from one 
of two representative experiments following incubation with peptides from the following proteins: NA derived from x31, NA de-
rived from PR8, M1, M2, NS1, and NS2 (all derived from x31).
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NS2) and matrix (M1 and M2) proteins of x31 (Figure 2). 
In addition, peptides from the HA and NA proteins of 
PR8 virus did not elicit positive responses from the x31-
primed spleen cells (Figure 1 and Figure 2), consistent 
with the relatively limited sequence homology between 
these proteins in the x31 and PR8 viruses. As expected, 
the screen clearly identified the regions of NP that had 
previously been reported by Gao et al. to contain an I-Ab 
epitope (NP261–290 and NP411–435) [9, 10]. These regions are 
indicated by the yellow bars in Figure 1.
Since the splenocytes used for the ELISpot assay in-
cluded both CD4 and CD8 cells, the data did not dis-
criminate between MHC class II- and class I-restricted re-
sponses. Although class I peptides are typically shorter 
than the 15-mer peptides synthesized for this study, it is 
known that 15 mer peptides can be presented to CD8+ 
T cells under these conditions, albeit with reduced effi-
ciency [28, 29]. Therefore, we scanned the ELISpot data 
for known immunodominant class I epitopes, NP366–374, 
PA224–233, and PB1703–711. Responses to all three of these 
epitopes were detected in the ELISpot screen as indicated 
by the blue bars in Figure 1. Taken together, these results 
suggested that our screen likely identified a combination 
of class I and class II-restricted epitopes.
3.2. Contributions of selected epitopes to T cell responses to 
primary x31 infection
Since we had identified a reasonable number of ep-
itopes that were not known class I-restricted epitopes, 
we assumed that most of these epitopes were likely to 
be class II-restricted CD4 T cell epitopes. To determine 
whether the RANKPEP algorithm could be used to accu-
rately predict the CD4 epitopes identified in our screen, 
we screened the x31 viral proteins using the RANKPEP 
algorithm and, using this program, identified a large 
number of peptides that were predicted to bind I-Ab 
with a range of efficiencies (Table 2 and data not shown). 
However, there was only a partial correlation with the 
ELISpot data (Table 2 and data not shown), and many 
epitopes identified in our functional screen were not 
identified by the RANKPEP program. Interestingly, the 
algorithm did predict two potentially strong I-Ab bind-
ing peptides in the NP261–290 region defined by Gao et al.; 
266LRGSVAHKS274 and 277PACVYGPAVA286 (Table 2), 
suggesting that a subset of CD4 epitopes can be identi-
fied by this method.
Next, to further investigate the specificity of the T cell 
response to influenza virus infection, we selected 36 pep-
tides for additional characterization (Table 2). These pep-
tides were selected on the basis that (i) they gave greater 
than 20 ELISpots in two independent screening assays, 
and/or (ii) they had a RANKPEP score of greater than 
32% optimal (this score was selected as it typically iden-
tified the top 10% of predicted I-Ab binders in any given 
protein). We also excluded all peptides that contained 
known class I epitopes and peptides from the regions pre-
viously described by Gao et al. [9, 10]. Table 2 shows the 
list of 36 peptides (plus the Gao et al. peptides) with the 
corresponding ELISpot results and RANKPEP scores. 
Even though these peptides were the top candidates for 
I-Ab-restricted epitopes, there was not a direct correlation 
between the number of ELISpots elicited by these pep-
tides and their respective RANKPEP scores. For example, 
NP311–325 elicited strong ELISpot responses but was only 
20% optimal by RANKPEP whereas PA456–470 elicited 
weak ELISpot responses but was 38% optimal by RANK-
PEP (Table 2). Of 36 peptides in Table 2 that were posi-
tive by ELISpot, only six received a RANKPEP score of 
greater than 32%.
We next analyzed the capacity of the 36 selected pep-
tides to stimulate IFNγ production during an acute re-
sponse to influenza virus infection using an intracellular 
cytokine assay. This approach allowed us to: (i) con-
firm specific epitopes in an independent assay; (ii) iden-
tify those epitopes that made significant contributions to 
the acute response to infection and (iii) specifically distin-
guish class I and class II responses. C57BL/6 mice were 
intranasally infected with influenza virus and 10 days 
later cells were recovered from the lung airways. These 
cells were then assessed for their ability to produce IFNγ 
in an intracellular cytokine assay following stimulation 
with each of the 36 peptides (the known class I epitopes, 
NP366–374 and PA224–233, and the Gao peptide, NP276–290, 
were included as controls). As shown in Figure 3 almost 
all of the peptides tested induced IFNγ in these effector 
T cells and over half of the peptides induced IFNγ pro-
duction in greater than 1% of either the CD4 or CD8 T 
cell populations. Ten of these peptides stimulated CD4 
T cells, eight stimulated CD8 T cells, while two peptides 
stimulated both CD4 and CD8 T cells to produce IFNγ. 
Representative data from six of these peptides are shown 
on the right hand panel of Figure 3.
3.3. T cells specific for the HA211–225 and NP311–325 epitopes 
make substantial contributions to the primary CD4 T cell re-
sponse to influenza
We next took the two peptides that elicited the stron-
gest IFNγ production in the intracellular cytokine staining 
assay (HA211–225 and NP311–325) and re-synthesized them 
as purified peptides to confirm that they corresponded to 
bona fide epitopes. Intracellular cytokine staining analysis 
of these re-synthesized peptides confirmed that they were 
both class II-restricted epitopes and also demonstrated 
that the NP311–325 peptide did not stimulate CD8 T cells 
(data not shown). It is unclear why the crude NP311–325 
peptide gave an initial response as a mixed CD4 and CD8 
epitope. However, we noted that the peptide was origi-
nally synthesized in a well adjacent to the known NP366–
374/D
b epitope and we now speculate that there may have 
been some cross contamination either during the produc-
tion or subsequent handling of the peptides. We next an-
alyzed the kinetics of the primary T cell response to the 
purified HA211–225 and NP311–325 epitopes. As shown in 
Figure 4A, both epitopes stimulated strong CD4+  T  cell 
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responses that can be first detected on day 8 post infec-
tion in the lung airways. The frequency of HA211–225 and 
NP311–325 specific cells peaked at 10% and 11%, respec-
tively, of the total CD4 cells. Since 67% of the total CD4 
T cells in the lung airways rapidly respond to activation 
with PMA and ionomycin treatment, we conclude that 
approximately 31% of the total influenza-specific CD4 T 
cells in the lung airways are specific for the HA211–225 and 
NP311–325 epitopes (Figure 4B). Together, these data con-
firm that HA211–225 and NP311–325 are bona fide class II-re-
stricted epitopes and further demonstrate that they are 
relatively dominant epitopes in the class II-restricted 
CD4+ T cell response following influenza virus infection 
of C57BL/6 mice.
Table 2. Amino acid sequence, ELISpot results, and RANKPEP results from influenza virus peptides selected for further 
investigation
Peptide name                      Sequence                                                           ELISpot                          RANKPEP                               RANKPEP  
                                                                                                                                                                                           resultsa                                            (Rank)b                                            (% Optimal)c
HA 201–215 PSTNQEQTSLYVQAS 33/14  
HA 206–220 EQTSLYVQASGRVTV 46/28 3 33.61
HA 211–225 YVQASGRVTVSTRRS 43/35 3 33.61
HA 261–275 INSNGNLIAPRGYFK 42/20  
HA 276–290 MRTGKSSIMRSDAPI 27/19 23 17.53
HA 321–335 CPKYVKQNTLKLATG 32/37 34 14.04
HA 326–340 KQNTLKLATGMRNVP 57/30 30 15.75
HA 441–455 AELLVALENQHTIDL 47/70  
HA 446–460 ALENQHTIDLTDSEM 22/42  
NP 91–105 KTGGPIYRRVNGKWM 25/17 2 38.05
NP 106–120 RELILYDKEEIRRIW 15/26  
NP 136–150 MMIWHSNLNDATYQR 26/14 22 17.72
NP 146–160 ATYQRTRALVRTGMD 30/17 5 27.89
NP 151–165 TRALVRTGMDPRMCS 48/22  
NP 161–175 PRMCSLMQGSTLPRR 45/22 47 8.96
NP 196–210 MIKRGINDRNFWRGE 30/21  
NP 201–215 INDRNFWRGENGRKT 34/39  
NP 206–220 FWRGENGRKTRIAYE 91/82  
NP 211–225 NGRKTRIAYERMCNI 82/61  
NP 216–230 RIAYERMCNILKGKF 44/43 49 8.53
NP 311–325 QVYSLIRPNENPAHK 38/41 14 19.98
NP 316–330 IRPNENPAHKSQLVW 20/23  
NP 326–340 SQLVWMACHSAAFED 26/17 41 10.71
PA 251–265 KEVNARIEPFLKTTP 26/14  
PA 256–270 RIEPKLKTTPRPLRL 29/17 22 18.00
PA 276–290 CSQRSKFLLMDALKL 26/27 30 15.83
PA 311–325 MRTFFGWKEPNVVKP 11/14 2 37.96
PA 316–330 GWKEPNVVKPHEKGI 16/16 2 37.96
PA 411–425 FNKACELTDSSWIEL 29/12 24 17.21
PA 456–470 RATEYIMKGVYINTA 18/13 1 38.11
NS2 91–105 ENSFEQITFMQALHL 11/61 1 21.32
PB2 91–105 VSPLAVTWWNRNGPM 20/20 33 14.86
PB2 106–120 TNTVHYPKIYKTYFE 32/17 21 19.35
PB2 196–210 CKISPLMVAYMLERE 42/30  
M1 201–215 EAMEVASQARQMVQA 12/32  
M1 211–225 QMVQAMITIGTHPSS 11/29 5 23.73
Region previously identified by Gao et al. [9, 10]
 NP 261–275 RSALILRGSVAHKSC 28/13 12 22.37
 NP 266–280 LRGSVAHKSCLPACV 56/30 12 22.37
 NP 271–285 AHKSCLPACVYGPAV 47/23 6 27.67
 NP 276–290 LPACVYGPAVASGYD 100/69 3 32.96
Brackets indicate overlapping peptides.
a Number of ELISpots from 105 spleen cells, determined in two independent experiments (experiment 1/experiment 2).
b Relative rank of the predicted peptide within the input protein.
c Percentile score of the predicted peptide relative to that of the sequence that yields the maximum score for the selected profile (I-Ab).
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3.4. The HA211–225 epitope is presented in the lungs and local 
draining lymph nodes during influenza virus infection
To further investigate the characteristics of the HA211–
225/A
b epitope, we generated a panel of T cell hybridomas. 
Spleen cells from mice that had recovered from a prior x31 
infection were stimulated in vitro with the HA211–225 pep-
tide and subsequently fused to a lacZ expressing variant 
of BW5147 [19]. The resulting hybridomas were screened 
for reactivity to the HA211–225 peptide and one hybridoma, 
H-#-SM101.3, was selected for further study. This hy-
bridoma was re-cloned and was shown to specifically re-
spond to the HA211–225 peptide pulsed L cells transfected 
with the I-Ab molecule (Figure 5A). The hybridoma also 
responded to syngeneic spleen cells infected with various 
doses of x31 influenza virus (Figure 5B). We next used 
the H-#-SM101.3 hybridoma to investigate the presenta-
tion of the HA211–225/A
b epitope ex vivo by antigen pre-
senting cells isolated from infected mice. Cells were iso-
lated from the lung airways, lung parenchyma, MLN, and 
spleen on days 4 (Figure 5C) and 6 (Figure 5D) post influ-
enza virus infection. Increasing numbers of cells from in-
fected mice were then cultured with the H-#-SM101.3 hy-
brid and the number of hybridoma cells responding to 
Figure 3. IFNγ production by antigen-specific CD4+ and CD8+ T cells on day 10 post infection. C57BL/6 mice were intranasally 
infected with 300 EID50 x31 influenza virus. On day 10 post infection, lung cells were collected and incubated for 5 h in the pres-
ence of the indicated peptide and Brefeldin A. Following stimulation, the cells were stained with anti-CD4 FITC, anti-CD8 PerCP, 
anti-IFNγ PE, and anti-CD44 allophycocyanin. Shown are the percentages of CD4 or CD8 cells producing IFNγ following stimula-
tion with the indicated peptide from one of two representative experiments. Also shown are representative FACs plots. Brackets 
indicate overlapping peptides.
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the HA211–225 peptide was determined one day later. As 
shown in Figure 5 panels C and D, cells presenting the 
HA211–225/A
b epitope were clearly detected at days 4 and 
6 in the lung airways, lung parenchyma, and MLN, but 
not in the spleen. Extrapolation of the titration curves in 
Figure 4 indicates that at least 1 in 1000 cells in the lungs 
and MLN are presenting the HA211–225/A
b epitope at both 
time points. Together, these data indicate that the HA211–
225/A
b epitope is widely expressed during the course of 
an influenza virus infection.
3.5. Partial control of viral infection in HA211–225 vaccinated 
mice
To investigate the capacity of T cells specific for the 
HA211–225/A
b epitope to mediate antiviral control, we vac-
cinated mice with dendritic cells that had been pulsed 
with the HA211–225 peptide (control mice were left unvac-
cinated). Three weeks post vaccination, the mice were 
boosted with peptide emulsified in incomplete Freud’s 
adjuvant and then infected with x31 influenza virus 2 
weeks later. The absolute numbers of antigen-specific 
T cells in the secondary lymphoid organs and the viral 
loads in the lungs were determined on various days post-
infection. Vaccination with dendritic cells pulsed with the 
HA211–225 peptide did not significantly alter the number 
of CD8+ T cells migrating to the lungs following infection 
(data not shown). However, HA211–225/A
b-specific cells 
were detected earlier in the lymphoid organs of vacci-
nated mice as compared to unvaccinated mice (day 6 ver-
sus day 8) (Figure 6A). In addition, substantially greater 
numbers of antigen-specific T cells were detected in vac-
cinated mice on day 8 post-infection (Figure 6A). Analy-
sis of viral loads indicated that there was a significant re-
duction in viral titers on days 4 and 6 in the vaccinated 
mice (Figure 6B). However, viral clearance was not ac-
celerated, with both vaccinated and unvaccinated mice 
clearing virus on day 12 (Figure 6B). Together these data 
indicate that vaccination with the HA211–225 peptide re-
sulted in a significantly enhanced T cell response to viral 
challenge and a corresponding decrease viral titers in the 
lungs. However, it did not result in the accelerated clear-
ance of virus from the lungs.
4. Discussion
A major limitation in our understanding of the CD4+ T 
cell response to influenza virus infection has been the lack 
of information on the numbers, source proteins, and rel-
ative contributions of class II epitopes that drive the re-
sponse. To begin to address this problem, we undertook a 
peptide screen of all the major influenza virus proteins to 
identify specific epitopes in C57BL/6 mice. This approach 
identified a large number of T cell epitopes that were de-
rived predominantly from a relatively limited number of 
proteins. We had initially speculated that the number of 
epitopes would reflect the length of the protein and its 
relative abundance in infected cells. Consistent with this, 
the nucleoprotein and hemagglutinin proteins contained 
large numbers of epitopes. However, the neuraminidase 
protein, which is also relatively abundant, did not con-
tain any I-Ab-restricted epitopes at all and the acidic poly-
merase protein, which has a relatively low abundance, 
appeared to contain multiple epitopes. It should be noted 
that although no epitopes were detected in the NA pro-
tein, this did not appear to reflect a general feature of 
this protein as multiple epitopes were identified in x31 
NA protein in a parallel screen with BALB/c (H-2d) mice 
(data not shown). As expected, there was no cross-reac-
tivity between the HA and NA proteins derived from x31 
and PR8 viruses in C57BL/6 mice. This is consistent with 
reports that these proteins do not elicit cross-reactive an-
tibodies or T cell responses [30, 31].
Figure 4. Kinetics of the antigen-specific CD4+ T cell response 
following influenza virus infection. C57BL/6 mice were intra-
nasally infected with 300 EID50 x31 influenza virus. Panel A: 
On days 4, 6, 8, 10, and 12 post infection, cells from the lung 
airways were collected and incubated for 5 h in the presence 
of the HA211–225 or NP311–325 peptide and Brefeldin A. Follow-
ing stimulation, the cells were stained with anti-CD4 FITC, 
anti-CD8 PerCP, anti-IFNγ PE, and anti-CD44 allophycocya-
nin. Shown is the number of epitope-specific CD4+ T cells on 
the different days post infection. Panel B shows the percentage 
of lung airway cells producing IFNγ following stimulation on 
day 10 post infection.
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An important question raised by these studies is what 
is the absolute number of class II-restricted epitopes in-
volved in the response to infection? Any analysis of the 
ELISpot data must take into account that: (i) a single ep-
itope can reside on up to three neighboring peptides; (ii) 
there is potential inclusion of class I-restricted epitopes 
and (iii) the data include some false positives. The issue of 
adjacent peptides and known class I epitopes is easily ad-
dressed, and taking these issues into account, we estimate 
that there are approximately 60 putative epitopes in H-2b 
mice (approximately 10 each in HA and PB2 and 20 each 
in NP and PA). The issue of false positives is more diffi-
cult to address. However, we can estimate the frequency 
of real class II epitopes among positive responses based 
on the analysis of a selected set of peptides in Figure 3. 
In this case, we analyzed 36 peptides that corresponded 
to 21 putative epitopes (taking into account overlapping 
peptides and excluding peptides that were only pos-
itive in the RANKPEP analysis). Ten of them (48%) ap-
peared to be real class II-restricted epitopes that elicited 
a significant T cell response in an independent intracel-
lular cytokine assay (greater than 1% of CD4+ T  cells  in 
the lung airways during an acute response to infection). 
Thus, we speculate that about 48% of the 60 putative epit-
opes (about 29 epitopes) identified in the entire screen are 
likely to be real epitopes. This is in the same range as the 
number of class I-restricted epitopes that have been iden-
tified in this MHC haplotype (16 Kb and Db-restricted ep-
itopes) [8, 32]. Moreover, two of the epitopes, HA211–225/
Ab and NP311–325/A
b, were shown dominate the CD4+ T 
cell response to infection, accounting for 31% of the CD4+ 
T cells present in the lung airways at the peak of the re-
sponse. This is very similar to the pattern of immuno-
dominance in the CD8+ T cell response where a limited 
number of epitopes dominate the entire response [8, 32]. 
However, it should be noted that C57BL/6 mice only ex-
press a single MHC class II molecule (I-Ab) due to the de-
letion of the I-Eα gene. Thus, our estimate of the breadth 
of the CD4+ T cell repertoire in C57BL/6 mice may under-
estimate the breadth of the repertoire in mice that express 
multiple MHC class II molecules. Further estimation of 
the repertoire will come from more detailed follow up 
analysis of the many putative epitopes identified in this 
study and a study of responses in mice expressing differ-
ent MHC haplotypes.
In addition to analyzing T cell responses using an 
ELISpot assay, we also analyzed the proteins using the 
RANKPEP algorithm. There was generally only a mod-
est correlation between the two approaches in terms of 
their ability to identify epitopes (Table 2). For example, 
Figure 5. Antigen presentation of the HA211–225/Ab epitope following infection with influenza virus. Panel A: clone H-#-SM101.3 
was screened using I-Ab transfected L cells incubated overnight with either the PB1703–711 or HA211–225 peptides at the indicated 
concentrations. The graphs show the number of positive Lac Z hybridomas per well (no more than 2000 spots were counted per 
well). Panel B: splenocytes were collected from uninfected mice and then infected in vitro with influenza virus at a multiplicity of 
infection of 0, 2, 10, or 50 for 4 h. The infected cells were irradiated and then plated in increasing numbers in a standard antigen 
presentation assay with the H-#-SM101.3 hybridoma. Panels C and D: mice were infected intranasally with x31 and cells from the 
lung airways, lung parenchyma, MLN, and spleens were collected on day 4 (panel C) or day 6 (panel D) post infection. Two-fold 
serial dilutions of cells were made in flat-bottom, 96-well plates starting at 105 cells/well and a standard antigen presentation as-
say was performed using the I-Ab HA211–225 restricted H-#-SM101.3 Lac Z-inducible hybridoma.
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the HA211–225/A
b epitope, which was found to contribute 
substantially to the CD4+ T cell response, was predicted 
by RANKPEP to be an immunodominant epitope with a 
33.6% optimal binding score and a rank of 3. However, 
another epitope, which also contributed to the CD4+  T 
cell response (NP311–325/A
b), was not predicted as an im-
munodominant epitope by RANKPEP with only a 20% 
optimal binding score and a rank of 14. In contrast, the 
PA456–470 peptide elicited weak ELISpot responses but was 
predicted by RANKPEP to be an optimal binder (38% op-
timal binding and number 1 rank). Therefore, while the 
RANKPEP algorithms can be useful in predicting immu-
nodominant epitopes, this methodology can result in both 
“false positives” (such as PA456–470) and “false negatives” 
(such as NP311–325).
A critical question regarding the inflammatory CD4+ 
T cell response has been its capacity to mediate protec-
tive immunity. Several studies have indicated that CD4+ 
T cells are generally not required for protection [33, 34]. 
However, evidence from a parainfluenza virus system 
suggests that CD4+ T cells can mediate substantial viral 
control against secondary challenge [16, 26] and stud-
ies using B cell deficient mice have suggested that CD4 T 
cells play an important role in enhancing protective anti-
body responses [35]. To address these issues in the influ-
enza virus system, we vaccinated mice with the HA211–225 
peptide and demonstrated that this resulted in signifi-
cant reductions in viral titers following a subsequent viral 
challenge. Interestingly, although the numbers of antigen-
specific CD4+ T cells was significantly enhanced in the 
vaccinated mice and persisted through day 12, this did 
not result in accelerated viral clearance. It is possible that 
this may reflect a general feature of inflammatory CD4+ 
T cell responses to influenza virus or the need for anti-
bodies to mediate late viral clearance. However, we have 
found that transgenic CD4+ effector T cells are able to me-
diate viral clearance and protection in an adoptive trans-
fer model, suggesting that the effect may be epitope-de-
pendent and reflect differences in effector functions, such 
as levels of TNFα secretion [36]. In this regard, we have 
shown that different MHC class I-restricted influenza vi-
rus epitopes differ in their capacity to elicit protective im-
mune responses. We are currently addressing these dif-
ferences experimentally.
In summary, the data presented here indicate that the 
numbers of influenza virus MHC class II and class I-re-
stricted epitopes in C57BL/6 mice are not significantly dif-
ferent and the T cell response to these epitopes tend to be 
dominated by only a limited number of epitopes. The data 
presented here will also provide a basis for further detailed 
studies of CD4+ T cell responses to influenza virus.
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Appendix B. Supplementary data
Supplemental Table 1.  x31 Influenza virus peptides
Peptide Sequence Elispota
HA 1-15 MKTIIALSYIFCLAL 9 14
HA 6-20 ALSYIFCLALGQDLP 2 6
HA 11-25 FCLALGQDLPGNDNS 1 5
HA 16-30 GQDLPGNDNSTATLC 3 4
HA 21-35 GNDNSTATLCLGHHA 2 3
HA 26-40 TATLCLGHHAVPNGT 7 2
HA 31-45 LGHHAVPNGTLVKTI 7 2
HA 36-50 VPNGTLVKTITDDQI 3 6
HA 41-55 LVKTITDDQIEVTNA 2 4
HA 46-60 TDDQIEVTNATELVQ 9 7
HA 51-65 EVTNATELVQSSSTG 5 5
HA 56-70 TELVQSSSTGKICNN 2 3
HA 61-75 SSSTGKICNNPHRIL 3 5
HA 66-80 KICNNPHRILDGIDC 4 4
HA 71-85 PHRILDGIDCTLIDA 4 7
HA 76-90 DGIDCTLIDALLGDP 3 5
HA 81-95 TLIDALLGDPHCDVF 2 5
HA 86-100 LLGDPHCDVFQNETW 6 8
HA 91-105 HCDVFQNETWDLFVE 4 8
HA 96-110 QNETWDLFVERSKAF 3 10
HA 101-115 DLFVERSKAFSNCYP 2 7
HA 106-120 RSKAFSNCYPYDVPD 3 6
HA 111-125 SNCYPYDVPDYASLR 5 5
HA 116-130 YDVPDYASLRSLVAS 5 4
HA 121-135 YASLRSLVASSGTLE 3 6
HA 126-140 SLVASSGTLEFITEG 2 4
HA 131-145 SGTLEFITEGFTWTG 4 4
HA 136-150 FITEGFTWTGVTQNG 3 2
HA 141-155 FTWTGVTQNGGSNAC 10 10
HA 146-160 VTQNGGSNACKRGPG 12 10
HA 151-165 GSNACKRGPGSGFFS 16 14
HA 156-170 KRGPGSGFFSRLNWL 6 5
HA 161-175 SGFFSRLNWLTKSGS 3 11
HA 166-180 RLNWLTKSGSTYPVL 9 4
HA 171-185 TKSGSTYPVLNVTMP 1 7
HA 176-190 TYPVLNVTMPNNDNF 0 6
HA 181-195 NVTMPNNDNFDKLYI 10 10
HA 186-200 NNDNFDKLYIWGIHH 2 4
HA 191-205 DKLYIWGIHHPSTNQ 11 4
HA 196-210 WGIHHPSTNQEQTSL 14 16
HA 201-215 PSTNQEQTSLYVQAS 33 14
HA 206-220 EQTSLYVQASGRVTV 46 28
HA 211-225 YVQASGRVTVSTRRS 43 35
HA 216-230 GRVTVSTRRSQQTII 3 5
HA 221-235 STRRSQQTIIPNIGS 2 8
HA 226-240 QQTIIPNIGSRPWVR 2 4
HA 231-245 PNIGSRPWVRGLSSR 4 8
HA 236-250 RPWVRGLSSRISIYW 3 6
Peptide Sequence Elispota
HA 241-255 GLSSRISIYWTIVKP 1 4
HA 246-260 ISIYWTIVKPGDVLV 3 5
HA 251-265 TIVKPGDVLVINSNG 2 5
HA 256-270 GDVLVINSNGNLIAP 2 9
HA 261-275 INSNGNLIAPRGYFK 42 20
HA 266-280 NLIAPRGYFKMRTGK 5 13
HA 271-285 RGYFKMRTGKSSIMR 1 10
HA 276-290 MRTGKSSIMRSDAPI 27 19
HA 281-295 SSIMRSDAPIDTCIS 4 5
HA 286-300 SDAPIDTCISECITP 1 2
HA 291-305 DTCISECITPNGSIP 0 4
HA 296-310 ECITPNGSIPNDKPF 0 6
HA 301-315 NGSIPNDKPFQNVNK 3 2
HA 306-320 NDKPFQNVNKITYGA 4 4
HA 311-325 QNVNKITYGACPKYV 9 12
HA 316-330 ITYGACPKYVKQNTL 17 14
HA 321-335 CPKYVKQNTLKLATG 32 37
HA 326-340 KQNTLKLATGMRNVP 57 30
HA 331-345 KLATGMRNVPEKQTR 3 3
HA 336-350 MRNVPEKQTRGLFGA 6 6
HA 341-355 EKQTRGLFGAIAGFI 5 8
HA 346-360 GLFGAIAGFIENGWE 2 4
HA 351-365 IAGFIENGWEGMIDG 4 2
HA 356-370 ENGWEGMIDGWYGFR 2 4
HA 361-375 GMIDGWYGFRHQNSE 2 4
HA 366-380 WYGFRHQNSEGTGQA 1 2
HA 371-385 HQNSEGTGQAADLKS 7 10
HA 376-390 GTGQAADLKSTQAAI 18 20
HA 381-395 ADLKSTQAAIDQING 17 14
HA 386-400 TQAAIDQINGKLNRV 7 16
HA 391-405 DQINGKLNRVIEKTN 11 12
HA 396-410 KLNRVIEKTNEKFHQ 5 2
HA 401-415 IEKTNEKFHQIEKEF 3 2
HA 406-420 EKFHQIEKEFSEVEG 1 3
HA 411-425 IEKEFSEVEGRIQDL 4 1
HA 416-430 SEVEGRIQDLEKYVE 0 3
HA 421-435 RIQDLEKYVEDTKID 1 4
HA 426-440 EKYVEDTKIDLWSYN 15 10
HA 431-445 DTKIDLWSYNAELLV 12 6
HA 436-450 LWSYNAELLVALENQ 10 16
HA 441-455 AELLVALENQHTIDL 47 70
HA 446-460 ALENQHTIDLTDSEM 22 42
HA 451-465 HTIDLTDSEMNKLFE 15 14
HA 456-470 TDSEMNKLFEKTRRQ 1 3
HA 461-475 NKLFEKTRRQLRENA 1 2
HA 466-480 KTRRQLRENAEEMGN 2 3
HA 471-485 LRENAEEMGNGCFKI 3 3
HA 476-490 EEMGNGCFKIYHKCD 8 4
HA 481-495 GCFKIYHKCDNACIE 1 6
HA 486-500 YHKCDNACIESIRNG 5 5
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Peptide Sequence Elispota
HA 491-505 NACIESIRNGTYDHD 18 14
HA 496-510 SIRNGTYDHDVYRDE 13 11
HA 501-515 TYDHDVYRDEALNNR 9 3
HA 506-520 VYRDEALNNRFQIKG 4 13
HA 511-525 ALNNRFQIKGVELKS 3 8
HA 516-530 FQIKGVELKSGYKDW 3 5
HA 521-535 VELKSGYKDWILWIS 4 12
HA 526-540 GYKDWILWISFAISC 2 4
HA 531-545 ILWISFAISCFLLCV 0 7
HA 536-550 FAISCFLLCVVLLGF 0 7
HA 541-555 FLLCVVLLGFIMWAC 8 3
HA 546-560 VLLGFIMWACQRGNI 1 6
HA 551-565 IMWACQRGNIRCNI 3 4
HA 556-566 QRGNIRCNICI 2 4
NA 1-15 MNPNQKIITIGSVSL 1 2
NA 6-20 KIITIGSVSLTIATV 0 5
NA 11-25 GSVSLTIATVCFLMQ 4 6
NA 16-30 TIATVCFLMQIAILV 3 5
NA 21-35 CFLMQIAILVTTVTL 0 6
NA 26-40 IAILVTTVTLHFKQY 1 4
NA 31-45 TTVTLHFKQYECDSP 1 5
NA 36-50 HFKQYECDSPASNQV 5 3
NA 41-55 ECDSPASNQVMPCEP 9 5
NA 46-60 ASNQVMPCEPIIIER 1 8
NA 51-65 MPCEPIIIERNITEI 6 8
NA 56-70 IIIERNITEIVYLNN 2 3
NA 61-75 NITEIVYLNNTTIEK 0 2
NA 66-80 VYLNNTTIEKEICPK 2 3
NA 71-85 TTIEKEICPKVVEYR 2 3
NA 76-90 EICPKVVEYRNWSKP 4 7
NA 81-95 VVEYRNWSKPQCQIT 2 5
NA 86-100 NWSKPQCQITGFAPF 1 6
NA 91-105 QCQITGFAPFSKDNS 4 5
NA 96-110 GFAPFSKDNSIRLSA 3 6
NA 101-115 SKDNSIRLSAGGDIW 2 8
NA 106-120 IRLSAGGDIWVTREP 3 5
NA 111-125 GGDIWVTREPYVSCD 4 10
NA 116-130 VTREPYVSCDHGKCY 1 1
NA 121-135 YVSCDHGKCYQFALG 0 4
NA 126-140 HGKCYQFALGQGTTL 0 6
NA 131-145 QFALGQGTTLDNKHS 1 7
NA 136-150 QGTTLDNKHSNDTIH 3 6
NA 141-155 DNKHSNDTIHDRIPH 1 4
NA 146-160 NDTIHDRIPHRTLLM 1 2
NA 151-165 DRIPHRTLLMNELGV 0 3
NA 156-170 RTLLMNELGVPFHLG 2 3
NA 161-175 NELGVPFHLGTRQVC 4 5
NA 166-180 PFHLGTRQVCIAWSS 1 4
NA 171-185 TRQVCIAWSSSSCHD 2 6
NA 176-190 IAWSSSSCHDGKAWL 2 7
Peptide Sequence Elispota
NA 181-195 SSCHDGKAWLHVCIT 2 5
NA 186-200 GKAWLHVCITGDDKN 2 6
NA 191-205 HVCITGDDKNATASF 1 3
NA 196-210 GDDKNATASFIYDGR 1 6
NA 201-215 ATASFIYDGRLVDSI 4 12
NA 206-220 IYDGRLVDSIGSWSQ 1 6
NA 211-225 LVDSIGSWSQNILRT 2 5
NA 216-230 GSWSQNILRTQESEC 3 6
NA 221-235 NILRTQESECVCING 2 5
NA 226-240 QESECVCINGTCTVV 3 4
NA 231-245 VCINGTCTVVMTDGS 1 6
NA 236-250 TCTVVMTDGSASGRA 2 3
NA 241-255 MTDGSASGRADTRIL 2 4
NA 246-260 ASGRADTRILFIEEG 1 5
NA 251-265 DTRILFIEEGKIVHI 3 4
NA 256-270 FIEEGKIVHISPLSG 2 5
NA 261-275 KIVHISPLSGSAQHV 3 3
NA 266-280 SPLSGSAQHVEECSC 2 6
NA 271-285 SAQHVEECSCYPRYP 1 4
NA 276-290 EECSCYPRYPGVRCI 2 14
NA 281-295 YPRYPGVRCICRDNW 1 4
NA 286-300 GVRCICRDNWKGSNR 0 7
NA 291-305 CRDNWKGSNRPVVDI 2 7
NA 296-310 KGSNRPVVDINMEDY 3 4
NA 301-315 PVVDINMEDYSIDSS 0 3
NA 306-320 NMEDYSIDSSYVCSG 2 2
NA 311-325 SIDSSYVCSGLVGDT 2 4
NA 316-330 YVCSGLVGDTPRNDD 3 13
NA 321-335 LVGDTPRNDDRSSNS 0 6
NA 326-340 PRNDDRSSNSNCRNP 0 3
NA 331-345 RSSNSNCRNPNNERG 1 2
NA 336-350 NCRNPNNERGNQGVK 1 4
NA 341-355 NNERGNQGVKGWAFD 1 4
NA 346-360 NQGVKGWAFDNGDDV 2 6
NA 351-365 GWAFDNGDDVWMGRT 3 4
NA 356-370 NGDDVWMGRTISKDL 2 5
NA 361-375 WMGRTISKDLRSGYE 0 4
NA 366-380 ISKDLRSGYETFKVI 1 2
NA 371-385 RSGYETFKVIGGWST 2 7
NA 376-390 TFKVIGGWSTPNSKS 0 5
NA 381-395 GGWSTPNSKSQINRQ 0 7
NA 386-400 PNSKSQINRQVIVDS 1 3
NA 391-405 QINRQVIVDSDNRSG 2 3
NA 396-410 VIVDSDNRSGYSGIF 1 3
NA 401-415 DNRSGYSGIFSVEGK 1 10
NA 406-420 YSGIFSVEGKSCINR 1 4
NA 411-425 SVEGKSCINRCFYVE 2 10
NA 416-430 SCINRCFYVELIRGR 2 12
NA 421-435 CFYVELIRGRKQETR 2 4
NA 424-438 VELIRGRKQETRVWW 3 7
Un e v e n Di s t r i b U t i o n o f MHC Cl a s s  ii  ep i t o p e s  w i t H i n t H e in f l U e n z a vi r U s   Suppl. 2
Peptide Sequence Elispota
NA 429-443 GRKQETRVWWTSNSI 0 5
NA 434-448 TRVWWTSNSIVVFCG 0 4
NA 439-453 TSNSIVVFCGTSGTY 0 4
NA 444-458 VVFCGTSGTYGTGSW 3 8
NA 449-463 TSGTYGTGSWPDGAN 1 4
NA 454-468 GTGSWPDGANINFMP 1 4
NA 459-469 PDGANINFMPI 0 12
NP 1-15 MASQGTKRSYEQMET 4 5
NP 6-20 TKRSYEQMETDGERQ 9 6
NP 11-25 EQMETDGERQNATEI 3 10
NP 16-30 DGERQNATEIRASVG 2 15
NP 21-35 NATEIRASVGKMIGG 14 5
NP 26-40 RASVGKMIGGIGRFY 10 12
NP 31-45 KMIGGIGRFYIQMCT 5 6
NP 36-50 IGRFYIQMCTELKLS 10 10
NP 41-55 IQMCTELKLSDYEGR 3 3
NP 46-60 ELKLSDYEGRLIQNS 3 12
NP 51-65 DYEGRLIQNSLTIER 6 11
NP 56-70 LIQNSLTIERMVLSA 3 6
NP 61-75 LTIERMVLSAFDERR 9 12
NP 66-80 MVLSAFDERRNKYLE 17 5
NP 71-85 FDERRNKYLEEHPSA 3 3
NP 76-90 NKYLEEHPSAGKDPK 2 9
NP 81-95 EHPSAGKDPKKTGGP 2 8
NP 86-100 GKDPKKTGGPIYRRV 6 5
NP 91-105 KTGGPIYRRVNGKWM 25 17
NP 96-110 IYRRVNGKWMRELIL 9 13
NP 101-115 NGKWMRELILYDKEE 2 10
NP 106-120 RELILYDKEEIRRIW 15 26
NP 111-125 YDKEEIRRIWRQANN 8 2
NP 116-130 IRRIWRQANNGDDAT 8 12
NP 121-135 RQANNGDDATAGLTH 12 11
NP 126-140 GDDATAGLTHMMIWH 16 6
NP 131-145 AGLTHMMIWHSNLND 13 7
NP 136-150 MMIWHSNLNDATYQR 26 14
NP 141-155 SNLNDATYQRTRALV 12 16
NP 146-160 ATYQRTRALVRTGMD 30 17
NP 151-165 TRALVRTGMDPRMCS 48 22
NP 156-170 RTGMDPRMCSLMQGS 42 12
NP 161-175 PRMCSLMQGSTLPRR 45 22
NP 166-180 LMQGSTLPRRSGAAG 12 5
NP 171-185 TLPRRSGAAGAAVKG 3 5
NP 176-190 SGAAGAAVKGVGTMV 6 3
NP 181-195 AAVKGVGTMVMELVR 7 3
NP 186-200 VGTMVMELVRMIKRG 8 8
NP 191-205 MELVRMIKRGINDRN 12 16
NP 196-210 MIKRGINDRNFWRGE 30 21
NP 201-215 INDRNFWRGENGRKT 34 39
NP 206-220 FWRGENGRKTRIAYE 91 82
NP 211-225 NGRKTRIAYERMCNI 82 61
Peptide Sequence Elispota
NP 216-230 RIAYERMCNILKGKF 44 43
NP 221-235 RMCNILKGKFQTAAQ 64 8
NP 226-240 LKGKFQTAAQKAMMD 6 6
NP 231-245 QTAAQKAMMDQVRES 4 8
NP 236-250 KAMMDQVRESRNPGN 5 6
NP 241-255 QVRESRNPGNAEFED 2 0
NP 246-260 RNPGNAEFEDLTFLA 7 3
NP 251-265 AEFEDLTFLARSALI 8 5
NP 256-270 LTFLARSALILRGSV 6 4
NP 261-275 RSALILRGSVAHKSC 28 13
NP 266-280 LRGSVAHKSCLPACV 56 30
NP 271-285 AHKSCLPACVYGPAV 47 23
NP 276-290 LPACVYGPAVASGYD 100 69
NP 281-295 YGPAVASGYDFEREG 16 6
NP 286-300 ASGYDFEREGYSLVG 10 3
NP 291-305 FEREGYSLVGIDPFR 6 3
NP 296-310 YSLVGIDPFRLLQNS 22 2
NP 301-315 IDPFRLLQNSQVYSL 8 2
NP 306-320 LLQNSQVYSLIRPNE 34 8
NP 311-325 QVYSLIRPNENPAHK 38 41
NP 316-330 IRPNENPAHKSQLVW 20 23
NP 321-335 NPAHKSQLVWMACHS 22 7
NP 326-340 SQLVWMACHSAAFED 26 17
NP 331-345 MACHSAAFEDLRVLS 3 7
NP 336-350 AAFEDLRVLSFIKGT 5 15
NP 341-355 LRVLSFIKGTKVLPR 4 3
NP 346-360 FIKGTKVLPRGKLST 3 5
NP 351-365 KVLPRGKLSTRGVQI 2 10
NP 356-370 GKLSTRGVQIASNEN 18 14
NP 361-375 RGVQIASNENMETME 177 139
NP 366-380 ASNENMETMESSTLE 188 3
NP 371-385 METMESSTLELRSRY 28 13
NP 376-390 SSTLELRSRYWAIRT 7 2
NP 381-395 LRSRYWAIRTRSGGN 3 2
NP 386-400 WAIRTRSGGNTNQQR 6 4
NP 391-405 RSGGNTNQQRASAGQ 4 3
NP 396-410 TNQQRASAGQISIQP 2 4
NP 401-415 ASAGQISIQPTFSVQ 7 4
NP 406-420 ISIQPTFSVQRNLPF 2 3
NP 411-425 TFSVQRNLPFDRTTI 3 4
NP 416-430 RNLPFDRTTIMAAFN 26 8
NP 421-435 DRTTIMAAFNGNTEG 6 10
NP 423-437 TIMAAFNGNTEGRTS 24 11
NP 428-442 FNGNTEGRTSDMRTE 1 3
NP 433-447 EGRTSDMRTEIIRMM 3 2
NP 438-452 DMRTEIIRMMESARP 8 7
NP 443-457 IIRMMESARPEDVSF 4 14
NP 448-462 ESARPEDVSFQGRGV 3 3
NP 453-467 EDVSFQGRGVFELSD 8 4
NP 458-472 QGRGVFELSDEKAAS 2 3
Suppl. 3  Cr o w e e t a l .  i n  Va c c i n e  24 (2006)
Peptide Sequence Elispota
NP 463-477 FELSDEKAASPIVPS 4 7
NP 468-482 EKAASPIVPSFDMSN 3 3
NP 473-487 PIVPSFDMSNEGSYF 0 4
NP 478-493 FDMSNEGSYFFGDNA 0 2
NP 484-498 EGSYFFGDNAEEYDN 0 5
NP 489-498 FGDNAEEYDN 2 3
PA 1-15 MEDFVRQCFNPMIVE 5 2
PA 6-20 RQCFNPMIVELAEKT 3 8
PA 11-25 PMIVELAEKTMKEYG 2 6
PA 16-30 LAEKTMKEYGEDLKI 0 8
PA 21-35 MKEYGEDLKIETNKF 4 8
PA 26-40 EDLKIETNKFAAICT 9 4
PA 31-45 ETNKFAAICTHLEVC 3 12
PA 36-50 AAICTHLEVCFMYSD 3 8
PA 41-55 HLEVCFMYSDFHFIN 5 10
PA 46-60 FMYSDFHFINEQGES 6 10
PA 51-65 FHFINEQGESIIVEL 9 6
PA 56-70 EQGESIIVELGDPSA 1 7
PA 61-75 IIVELGDPSALLKHR 3 10
PA 66-80 GDPSALLKHRFEIIE 2 10
PA 71-85 LLKHRFEIIEGRDRT 7 7
PA 76-90 FEIIEGRDRTMAWTV 1 9
PA 81-95 GRDRTMAWTVVNSIC 4 10
PA 86-100 MAWTVVNSICNTTGA 9 12
PA 91-105 VNSICNTTGAEKPKF 4 14
PA 96-110 NTTGAEKPKFLPDLY 2 9
PA 101-115 EKPKFLPDLYDYKEN 2 6
PA 106-120 LPDLYDYKENRFIEI 6 8
PA 111-125 DYKENRFIEIGVTRR 4 4
PA 116-130 RFIEIGVTRREVHIY 1 4
PA 121-135 GVTRREVHIYYLEKA 6 1
PA 126-140 EVHIYYLEKANKIKS 21 4
PA 131-145 YLEKANKIKSEKTHI 4 7
PA 136-150 NKIKSEKTHIHIFSF 2 6
PA 141-155 EKTHIHIFSFTGEEM 3 5
PA 146-160 HIFSFTGEEMATKAD 14 5
PA 151-165 TGEEMATKADYTLDE 9 3
PA 156-170 ATKADYTLDEESRAR 5 4
PA 161-175 YTLDEESRARIKTRL 15 6
PA 166-180 ESRARIKTRLFTIRQ 12 4
PA 171-185 IKTRLFTIRQEMASR 6 3
PA 176-190 FTIRQEMASRGLWDS 3 3
PA 181-195 EMASRGLWDSFRQSE 13 3
PA 186-200 GLWDSFRQSERGEET 4 4
PA 191-205 FRQSERGEETIEERF 5 22
PA 196-210 RGEETIEERFEITGT 12 15
PA 201-215 IEERFEITGTMRKLA 5 8
PA 206-220 EITGTMRKLADQSLP 17 8
PA 211-225 MRKLADQSLPPNFSS 13 5
PA 216-230 DQSLPPNFSSLENFR 134 24
Peptide Sequence Elispota
PA 221-235 PNFSSLENFRAYVDG 293 53
PA 226-240 LENFRAYVDGFEPNG 74 8
PA 231-245 AYVDGFEPNGYIEGK 7 4
PA 236-250 FEPNGYIEGKLSQMS 0 3
PA 241-255 YIEGKLSQMSKEVNA 2 3
PA 246-260 LSQMSKEVNARIEPF 23 14
PA 251-265 KEVNARIEPFLKTTP 26 14
PA 256-270 RIEPFLKTTPRPLRL 29 17
PA 261-275 LKTTPRPLRLPNGPP 23 3
PA 266-280 RPLRLPNGPPCSQRS 32 6
PA 271-285 PNGPPCSQRSKFLLM 48 6
PA 276-290 CSQRSKFLLMDALKL 26 27
PA 281-295 KFLLMDALKLSIEDP 27 6
PA 286-300 DALKLSIEDPSHEGE 14 3
PA 291-305 SIEDPSHEGEGIPLY 4 5
PA 296-310 SHEGEGIPLYDAIKC 2 9
PA 301-315 GIPLYDAIKCMRTFF 10 7
PA 306-320 DAIKCMRTFFGWKEP 2 9
PA 311-325 MRTFFGWKEPNVVKP 11 14
PA 316-330 GWKEPNVVKPHEKGI 16 16
PA 321-335 NVVKPHEKGINPNYL 19 8
PA 326-340 HEKGINPNYLLSWKQ 14 12
PA 331-345 NPNYLLSWKQVLAEL 6 3
PA 336-350 LSWKQVLAELQDIEN 19 6
PA 341-355 VLAELQDIENEEKIP 21 4
PA 346-360 QDIENEEKIPKTKNM 4 4
PA 351-365 EEKIPKTKNMKKTSQ 3 6
PA 356-370 KTKNMKKTSQLKWAL 5 6
PA 361-375 KKTSQLKWALGENMA 2 4
PA 366-380 LKWALGENMAPEKVD 3 2
PA 371-385 GENMAPEKVDFDDCK 22 2
PA 376-390 PEKVDFDDCKDVGDL 4 6
PA 381-395 FDDCKDVGDLKQYDS 9 4
PA 386-400 DVGDLKQYDSDEPEL 3 5
PA 391-405 KQYDSDEPELRSLAS 18 3
PA 396-410 DEPELRSLASWIQNE 8 3
PA 401-415 RSLASWIQNEFNKAC 14 10
PA 406-420 WIQNEFNKACELTDS 24 10
PA 411-425 FNKACELTDSSWIEL 29 12
PA 416-430 ELTDSSWIELDEIGE 2 4
PA 421-435 SWIELDEIGEDVAPI 4 6
PA 436-440 ELDEIGEDVAPIEHI 2 8
PA 431-445 GEDVAPIEHIASMRR 13 8
PA 436-450 PIEHIASMRRNYFTS 5 3
PA 441-455 ASMRRNYFTSEVSHC 6 5
PA 446-460 NYFTSEVSHCRATEY 12 16
PA 451-465 EVSHCRATEYIMKGV 17 16
PA 456-470 RATEYIMKGVYINTA 18 13
PA 461-475 IMKGVYINTALLNAS 1 15
PA 466-480 YINTALLNASCAAMD 8 7
Un e v e n Di s t r i b U t i o n o f MHC Cl a s s  ii  ep i t o p e s  w i t H i n t H e in f l U e n z a vi r U s   Suppl. 4
Peptide Sequence Elispota
PA 471-185 LLNASCAAMDDFQLI 1 6
PA 476-490 CAAMDDFQLIPMISK 12 10
PA 481-495 DFQLIPMISKCRTKE 17 12
PA 486-500 PMISKCRTKEGRRKT 16 4
PA 491-505 CRTKEGRRKTNLYGF 7 3
PA 496-510 GRRKTNLYGFIIKGR 5 2
PA 501-515 NLYGFIIKGRSHLRN 3 2
PA 506-520 IIKGRSHLRNDTDVV 4 7
PA 511-525 SHLRNDTDVVNFVSM 2 4
PA 516-530 DTDVVNFVSMEFSLT 1 7
PA 521-535 NFVSMEFSLTDPRLE 4 5
PA 526-540 EFSLTDPRLEPHKWE 2 4
PA 531-545 DPRLEPHKWEKYCVL 6 3
PA 536-550 PHKWEKYCVLEIGDM 11 2
PA 541-555 KYCVLEIGDMLIRSA 8 3
PA 546-560 EIGDMLIRSAIGQVS 6 6
PA 551-565 LIRSAIGQVSRPMFL 2 6
PA 556-570 IGQVSRPMFLYVRTN 4 2
PA 561-575 RPMFLYVRTNGTSKI 7 3
PA 566-580 YVRTNGTSKIKMKWG 4 4
PA 571-585 GTSKIKMKWGMEMRR 1 3
PA 576-590 KMKWGMEMRRCLLQS 1 4
PA 581-595 MEMRRCLLQSLQQIE 5 11
PA 586-500 CLLQSLQQIESMIEA 1 16
PA 591-605 LQQIESMIEAESSVK 3 16
PA 596-610 SMIEAESSVKEKDMT 12 17
PA 601-615 ESSVKEKDMTKEFFE 7 32
PA 606-620 EKDMTKEFFENKSET 8 24
PA 611-625 KEFFENKSETWPIGE 6 5
PA 616-630 NKSETWPIGESPKGV 2 5
PA 621-635 WPIGESPKGVEESSI 3 2
PA 626-640 SPKGVEESSIGKVCR 3 2
PA 631-645 EESSIGKVCRTLLAK 4 5
PA 636-650 GKVCRTLLAKSVFNS 2 7
PA 641-655 TLLAKSVFNSLYASP 2 4
PA 646-660 SVFNSLYASPQLEGF 3 3
PA 651-665 LYASPQLEGFSAESR 1 8
PA 656-670 QLEGFSAESRKLLLI 0 1
PA 661-675 SAESRKLLLIVQALR 3 3
PA 666-680 KLLLIVQALRDNLEP 1 1
PA 671-685 VQALRDNLEPGTFDL 1 2
PA 676-690 DNLEPGTFDLGGLYE 0 1
PA 681-695 GTFDLGGLYEAIEEC 1 2
PA 686-700 GGLYEAIEECLINDP 3 1
PA 691-705 AIEECLINDPWVLLN 1 3
PA 696-710 LINDPWVLLNASWFN 2 8
PA 701-715 WVLLNASWFNSFLTH 4 7
PA 706-716 ASWFNSFLTHALS 1 1
PB1 1-15 MDVNPTLLFLKVPAQ 2 4
PB1 6-20 TLLFLKVPAQNAIST 1 7
Peptide Sequence Elispota
PB1 11-25 KVPAQNAISTTFPYT 0 2
PB1 16-30 NAISTTFPYTGDPPY 4 12
PB1 21-35 TFPYTGDPPYSHGTG 2 4
PB1 26-40 GDPPYSHGTGTGYTM 1 6
PB1 31-45 SHGTGTGYTMDTVNR 0 1
PB1 36-50 TGYTMDTVNRTHQYS 2 4
PB1 41-55 DTVNRTHQYSEKGRW 0 10
PB1 46-60 THQYSEKGRWTTNTE 0 10
PB1 51-65 EKGRWTTNTETGAPQ 2 5
PB1 56-70 TTNTETGAPQLNPID 0 6
PB1 61-75 TGAPQLNPIDGPLPE 2 5
PB1 66-80 LNPIDGPLPEDNEPS 3 40
PB1 71-85 GPLPEDNEPSGYAQT 9 6
PB1 76-90 DNEPSGYAQTDCVLE 4 12
PB1 81-95 GYAQTDCVLEVMAFL 5 7
PB1 86-100 DCVLEVMAFLEESHP 8 13
PB1 91-105 VMAFLEESHPGIFEN 0 11
PB1 96-110 EESHPGIFENSCIET 4 9
PB1 101-115 GIFENSCIETMEVVQ 9 6
PB1 106-120 SCIETMEVVQQTRVD 9 11
PB1 111-125 MEVVQQTRVDKLTQG 1 4
PB1 116-130 QTRVDKLTQGRQTYD 2 12
PB1 121-135 KLTQGRQTYDWTLNR 0 6
PB1 126-140 RQTYDWTLNRNQPAA 2 11
PB1 131-145 WTLNRNQPAATALAN 2 3
PB1 136-150 NQPAATALANTIEVF 2 6
PB1 141-155 TALANTIEVFRSNGL 5 4
PB1 146-160 TIEVFRSNGLTANES 1 12
PB1 151-165 RSNGLTANESGRLID 1 9
PB1 156-170 TANESGRLIDFLKDV 4 18
PB1 161-175 GRLIDFLKDVMESMN 1 7
PB1 166-180 FLKDVMESMNKEEMG 2 5
PB1 171-185 MESMNKEEMGITTHF 3 4
PB1 176-190 KEEMGITTHFQRKRR 1 6
PB1 181-195 ITTHFQRKRRVRDNM 2 5
PB1 186-200 QRKRRVRDNMTKKMI 3 3
PB1 191-205 VRDNMTKKMITQRTM 3 9
PB1 196-210 TKKMITQRTMGKKKQ 5 9
PB1 201-215 TQRTMGKKKQRLNKR 4 4
PB1 206-220 GKKKQRLNKRSYLIR 1 5
PB1 211-225 RLNKRSYLIRALTLN 2 6
PB1 216-230 SYLIRALTLNTMTKD 2 14
PB1 221-235 ALTLNTMTKDAERGK 6 3
PB1 226-240 TMTKDAERGKLKRRA 0 6
PB1 231-245 AERGKLKRRAIATPG 1 7
PB1 236-250 LKRRAIATPGMQIRG 0 8
PB1 241-255 IATPGMQIRGFVYFV 5 3
PB1 246-260 MQIRGFVYFVETLAR 2 11
PB1 251-265 FVYFVETLARSICEK 4 4
PB1 256-270 ETLARSICEKLEQSG 1 3
Suppl. 5  Cr o w e e t a l .  i n  Va c c i n e  24 (2006)
Peptide Sequence Elispota
PB1 261-275 SICEKLEQSGLPVGG 0 4
PB1 266-280 LEQSGLPVGGNEKKA 2 0
PB1 271-285 LPVGGNEKKAKLANV 2 4
PB1 276-290 NEKKAKLANVVRKMM 4 4
PB1 281-295 KLANVVRKMMTNSQD 2 32
PB1 286-300 VRKMMTNSQDTELSF 5 12
PB1 291-305 TNSQDTELSFTITGD 4 7
PB1 296-310 TELSFTITGDNTKWN 3 5
PB1 301-315 TITGDNTKWNENQNP 1 7
PB1 306-320 NTKWNENQNPRMFLA 0 16
PB1 311-325 ENQNPRMFLAMITYM 1 10
PB1 316-330 RMFLAMITYMTRNQP 1 9
PB1 321-335 MITYMTRNQPEWFRN 3 10
PB1 326-340 TRNQPEWFRNVLSIA 4 17
PB1 331-345 EWFRNVLSIAPIMFS 4 16
PB1 336-350 VLSIAPIMFSNKMAR 0 9
PB1 341-355 PIMFSNKMARLGKGY 1 7
PB1 346-360 NKMARLGKGYMFESK 2 6
PB1 351-365 LGKGYMFESKSMKLR 7 3
PB1 356-370 MFESKSMKLRTQIPA 0 6
PB1 361-375 SMKLRTQIPAEMLAS 0 7
PB1 366-380 TQIPAEMLASIDLKY 2 6
PB1 371-385 EMLASIDLKYFNDST 2 5
PB1 376-390 IDLKYFNDSTRKKIE 0 7
PB1 381-395 FNDSTRKKIEKIRPL 0 6
PB1 386-400 RKKIEKIRPLLIEGT 7 2
PB1 391-405 KIRPLLIEGTASLSP 3 2
PB1 396-410 LIEGTASLSPGMMMG 1 1
PB1 401-415 ASLSPGMMMGMFNML 6 5
PB1 406-420 GMMMGMFNMLSTVLG 0 15
PB1 411-425 MFNMLSTVLGVSILN 5 7
PB1 416-430 STVLGVSILNLGQKR 2 2
PB1 421-435 VSILNLGQKRYTKTT 0 3
PB1 426-440 LNLGQKRYTKTTYWW 0 4
PB1 431-445 KRYTKTTYWWDGLQS 3 8
PB1 436-450 TTYWWDGLQSSDDFA 2 7
PB1 441-455 DGLQSSDDFALIVNA 4 3
PB1 446-460 SDDFALIVNAPNHEG 1 5
PB1 451-465 LIVNAPNHEGIQAGV 2 7
PB1 456-470 PNHEGIQAGVDRFYR 2 11
PB1 461-475 IQAGVDRFYRTCKLL 6 4
PB1 466-480 DRFYRTCKLLGINMS 5 18
PB1 471-485 TCKLLGINMSKKKSY 2 6
PB1 476-490 GINMSKKKSYINRTG 5 4
PB1 481-495 KKKSYINRTGTFEFT 3 1
PB1 486-500 INRTGTFEFTSFFYR 6 1
PB1 491-505 TFEFTSFFYRYGFVA 7 19
PB1 496-510 SFFYRYGFVANFSME 3 16
PB1 501-515 YGFVANFSMELPSFG 7 22
PB1 506-520 NFSMELPSFGVSGIN 6 8
Peptide Sequence Elispota
PB1 511-525 LPSFGVSGINESADM 10 7
PB1 516-530 VSGINESADMSIGVT 2 2
PB1 521-535 ESADMSIGVTVIKNN 1 4
PB1 526-540 SIGVTVIKNNMINND 3 2
PB1 531-545 VIKNNMINNDLGPAT 4 3
PB1 536-550 MINNDLGPATAQMAL 3 1
PB1 541-555 LGPATAQMALQLFIK 8 1
PB1 546-560 AQMALQLFIKDYRYT 3 2
PB1 551-565 QLFIKDYRYTYRCHR 6 2
PB1 556-570 DYRYTYRCHRGDTQI 9 4
PB1 561-575 YRCHRGDTQIQTRRS 8 8
PB1 566-580 GDTQIQTRRSFEIKK 4 6
PB1 571-585 QTRRSFEIKKLWEQT 6 5
PB1 576-590 FEIKKLWEQTRSKAG 5 6
PB1 581-595 LWEQTRSKAGLLVSD 9 3
PB1 586-600 RSKAGLLVSDGGPNL 11 0
PB1 591-605 LLVSDGGPNLYNIRN 5 0
PB1 596-610 GGPNLYNIRNLHIPE 3 3
PB1 601-615 YNIRNLHIPEVCLKW 16 7
PB1 606-620 LHIPEVCLKWELMDE 5 4
PB1 611-625 VCLKWELMDEDYQGR 4 8
PB1 616-630 ELMDEDYQGRLCNPL 9 9
PB1 621-635 DYQGRLCNPLNPFVS 13 9
PB1 626-640 LCNPLNPFVSHKEIE 13 6
PB1 631-645 NPFVSHKEIESMNNA 10 5
PB1 636-650 HKEIESMNNAVMMPA 9 6
PB1 641-655 SMNNAVMMPAHGPAK 0 2
PB1 646-660 VMMPAHGPAKNMEYD 0 1
PB1 651-665 HGPAKNMEYDAVATT 6 2
PB1 656-670 NMEYDAVATTHSWIP 1 5
PB1 661-675 AVATTHSWIPKRNRS 3 2
PB1 666-680 HSWIPKRNRSILNTS 1 1
PB1 671-685 KRNRSILNTSQRGVL 0 2
PB1 676-690 ILNTSQRGVLGDEQM 1 4
PB1 681-695 QRGVLGDEQMYQRCC 3 2
PB1 686-700 GDEQMYQRCCNLFEK 2 1
PB1 691-705 YQRCCNLFEKFFPSS 4 3
PB1 696-710 NLFEKFFPSSSYRRP 2 0
PB1 701-715 FFPSSSYRRPVGISS 86 36
PB1 706-720 SYRRPVGISSMVEAM 12 8
PB1 711-725 VGISSMVEAMVSRAR 2 3
PB1 716-730 MVEAMVSRARIDARI 3 3
PB1 721-735 VSRARIDARIDFESG 2 5
PB1 726-740 IDARIDFESGRIKKE 4 3
PB1 731-745 DFESGRIKKEEFTEI 1 3
PB1 736-750 RIKKEEFTEIMKICS 2 4
PB1 741-755 EFTEIMKICSTIEEL 2 7
PB1 746-759 MKICSTIEELRRQK 6 4
PB1 751-759 TIEELRRQK 2 4
PB2 1-15 MERIKELRNLMSQSR 4 3
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Peptide Sequence Elispota
PB2 6-20 ELRNLMSQSRTREIL 2 1
PB2 11-25 MSQSRTREILTKTTV 3 3
PB2 16-30 TREILTKTTVDHMAI 12 11
PB2 21-35 TKTTVDHMAIIKKFT 3 5
PB2 26-40 DHMAIIKKFTSGRQE 4 6
PB2 31-45 IKKFTSGRQEKNPAL 2 7
PB2 36-50 SGRQEKNPALRMKWM 6 8
PB2 41-55 KNPALRMKWMMAMKY 9 6
PB2 46-60 RMKWMMAMKYPITAD 11 5
PB2 51-65 MAMKYPITADKRITE 7 8
PB2 56-70 PITADKRITEMIPER 4 4
PB2 61-75 KRITEMIPERNEQGQ 1 6
PB2 66-80 MIPERNEQGQTLWSK 4 7
PB2 71-85 NEQGQTLWSKMNDAG 5 15
PB2 76-90 TLWSKMNDAGSDRVM 7 7
PB2 81-95 MNDAGSDRVMVSPLA 4 6
PB2 86-100 SDRVMVSPLAVTWWN 13 10
PB2 91-105 VSPLAVTWWNRNGPM 20 20
PB2 96-110 VTWWNRNGPMTNTVH 19 22
PB2 101-115 RNGPMTNTVHYPKIY 14 12
PB2 106-120 TNTVHYPKIYKTYFE 32 17
PB2 111-125 YPKIYKTYFERVERL 1 4
PB2 116-130 KTYFERVERLKHGTF 6 6
PB2 121-135 RVERLKHGTFGPVHF 5 2
PB2 126-140 KHGTFGPVHFRNQVK 0 4
PB2 131-145 GPVHFRNQVKIRRRV 4 14
PB2 136-150 RNQVKIRRRVDINPG 8 4
PB2 141-155 IRRRVDINPGHADLS 8 13
PB2 146-160 DINPGHADLSAKEAQ 4 10
PB2 151-165 HADLSAKEAQDVIME 5 12
PB2 156-170 AKEAQDVIMEVVFPN 3 6
PB2 161-175 DVIMEVVFPNEVGAR 3 12
PB2 166-180 VVFPNEVGARILTSE 4 7
PB2 171-185 EVGARILTSESQLTI 3 8
PB2 176-190 ILTSESQLTITKEKK 12 7
PB2 181-195 SQLTITKEKKEELQD 3 6
PB2 186-200 TKEKKEELQDCKISP 4 9
PB2 191-205 EELQDCKISPLMVAY 5 11
PB2 196-210 CKISPLMVAYMLERE 42 30
PB2 201-215 LMVAYMLERELVRKT 3 4
PB2 206-220 MLERELVRKTRFLPV 2 5
PB2 211-225 LVRKTRFLPVAGGTS 6 3
PB2 216-230 RFLPVAGGTSSVYIE 7 6
PB2 221-235 AGGTSSVYIEVLHLT 11 10
PB2 226-240 SVYIEVLHLTQGTCW 5 5
PB2 231-245 VLHLTQGTCWEQMYT 2 7
PB2 236-250 QGTCWEQMYTPGGEV 1 5
PB2 241-255 EQMYTPGGEVRNDDV 8 2
PB2 246-260 PGGEVRNDDVDQSLI 3 3
PB2 251-265 RNDDVDQSLIIAARN 1 7
Peptide Sequence Elispota
PB2 256-270 DQSLIIAARNIVRRA 5 5
PB2 261-275 IAARNIVRRAAVSAD 6 3
PB2 266-280 IVRRAAVSADPLASL 7 10
PB2 271-285 AVSADPLASLLEMCH 10 5
PB2 276-290 PLASLLEMCHSTQIG 6 3
PB2 281-295 LEMCHSTQIGGIRMV 4 10
PB2 286-300 STQIGGIRMVDILRQ 5 6
PB2 291-305 GIRMVDILRQNPTEE 6 8
PB2 296-310 DILRQNPTEEQAVDI 4 3
PB2 301-315 NPTEEQAVDICKAAM 7 5
PB2 306-320 QAVDICKAAMGLRIS 5 4
PB2 311-325 CKAAMGLRISSSFSF 3 6
PB2 316-330 GLRISSSFSFGGFTF 11 12
PB2 321-335 SSFSFGGFTFKRTSG 12 12
PB2 326-340 GGFTFKRTSGSSVKR 1 10
PB2 331-345 KRTSGSSVKREEEVL 14 7
PB2 336-350 SSVKREEEVLTGNLQ 1 5
PB2 341-355 EEEVLTGNLQTLKIR 3 10
PB2 346-360 TGNLQTLKIRVHEGY 4 4
PB2 351-365 TLKIRVHEGYEEFTM 2 9
PB2 356-370 VHEGYEEFTMVGRRA 1 10
PB2 361-375 EEFTMVGRRATAILR 3 6
PB2 366-380 VGRRATAILRKATRR 4 7
PB2 371-385 TAILRKATRRLIQLI 6 13
PB2 376-390 KATRRLIQLIVSGRD 4 8
PB2 381-395 LIQLIVSGRDEQSIA 3 7
PB2 386-400 VSGRDEQSIAEAIIV 2 7
PB2 391-405 EQSIAEAIIVAMVFS 2 4
PB2 396-410 EAIIVAMVFSQEDCM 5 3
PB2 401-415 AMVFSQEDCMIKAVR 1 7
PB2 406-420 QEDCMIKAVRGDLNF 5 4
PB2 411-425 IKAVRGDLNFVNRAN 6 11
PB2 416-430 GDLNFVNRANQRLNP 8 14
PB2 421-435 VNRANQRLNPMHQLL 4 4
PB2 426-440 ANQRLNPMHQLLRHF 6 4
PB2 431-445 NPMHQLLRHFQKDAK 0 1
PB2 436-450 LLRHFQKDAKVLFQN 2 4
PB2 441-455 QKDAKVLFQNWGVEP 4 6
PB2 446-460 VLFQNWGVEPIDNVM 8 6
PB2 451-465 WGVEPIDNVMGMIGI 6 6
PB2 456-470 IDNVMGMIGILPDMT 4 5
PB2 461-475 GMIGILPDMTPSIEM 3 9
PB2 466-480 LPDMTPSIEMSMRGV 4 1
PB2 471-485 PSIEMSMRGVRISKM 4 6
PB2 476-490 SMRGVRISKMGVDEY 1 2
PB2 481-495 RISKMGVDEYSSTER 3 2
PB2 486-500 GVDEYSSTERVVVSI 2 4
PB2 491-505 SSTERVVVSIDRFLR 4 3
PB2 496-510 VVVSIDRFLRIRDQR 7 4
PB2 501-515 DRFLRIRDQRGNVLL 6 3
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Peptide Sequence Elispota
PB2 506-520 IRDQRGNVLLSPEEV 4 4
PB2 511-525 GNVLLSPEEVSETQG 10 7
PB2 516-530 SPEEVSETQGTEKLT 8 4
PB2 521-535 SETQGTEKLTITYSS 15 9
PB2 526-540 TEKLTITYSSSMMWE 4 2
PB2 531-545 ITYSSSMMWEINGPE 26 2
PB2 536-550 SMMWEINGPESVLVN 6 3
PB2 541-555 INGPESVLVNTYQWI 8 4
PB2 546-560 SVLVNTYQWIIRNWE 3 6
PB2 551-565 TYQWIIRNWETVKIQ 2 2
PB2 556-570 IRNWETVKIQWSQNP 7 4
PB2 561-575 TVKIQWSQNPTMLYN 3 6
PB2 566-580 WSQNPTMLYNKMEFE 8 3
PB2 571-585 TMLYNKMEFEPFQSL 5 2
PB2 576-590 KMEFEPFQSLVPKAI 3 2
PB2 581-595 PFQSLVPKAIRGQYS 2 2
PB2 586-600 VPKAIRGQYSGFVRT 12 2
PB2 591-605 RGQYSGFVRTLFQQM 3 3
PB2 596-610 GFVRTLFQQMRDVLG 8 5
PB2 601-615 LFQQMRDVLGTFDTA 3 1
PB2 606-620 RDVLGTFDTAQIIKL 5 1
PB2 611-625 TFDTAQIIKLLPFAA 4 3
PB2 616-630 QIIKLLPFAAAPPKQ 0 2
PB2 621-635 LPFAAAPPKQSRMQF 1 4
PB2 626-640 APPKQSRMQFSSFTV 0 4
PB2 631-645 SRMQFSSFTVNVRGS 2 3
PB2 636-650 SSFTVNVRGSGMRIL 2 4
PB2 641-655 NVRGSGMRILVRGNS 2 6
PB2 646-660 GMRILVRGNSPVFNY 2 9
PB2 651-665 VRGNSPVFNYNKATK 1 4
PB2 656-670 PVFNYNKATKRLTVL 6 20
PB2 661-675 NKATKRLTVLGKDAG 3 5
PB2 666-680 RLTVLGKDAGTLTED 3 2
PB2 671-685 GKDAGTLTEDPDEGT 6 1
PB2 676-690 TLTEDPDEGTAGVES 1 2
PB2 681-695 PDEGTAGVESAVLRG 1 4
PB2 686-700 AGVESAVLRGFLILG 1 1
PB2 691-705 AVLRGFLILGKEDKR 4 4
PB2 696-710 FLILGKEDKRYGPAL 3 5
PB2 701-715 KEDKRYGPALSINEL 5 44
PB2 706-720 YGPALSINELSNLAK 1 4
PB2 711-725 SINELSNLAKGEKAN 3 5
PB2 716-730 SNLAKGEKANVLIGQ 1 6
PB2 721-735 GEKANVLIGQGDVVL 1 10
PB2 726-740 VLIGQGDVVLVMKRK 5 5
PB2 731-745 GDVVLVMKRKRDSSI 13 5
PB2 734-748 VMKRKRDSSILTDSQ 0 8
PB2 737-751 RDSSILTDSQTATKR 0 29
PB2 742-756 LTDSQTATKRIRMAI 2 1
PB2 747-757 TATKRIRMAIN 1 3
Peptide Sequence Elispota
NS1 1-15 MDPNTVSSFQVDCFL 1 5
NS1 6-20 VSSFQVDCFLWHVRK 4 3
NS1 11-25 VDCFLWHVRKRVADQ 2 2
NS1 16-30 WHVRKRVADQELGDA 3 7
NS1 21-35 RVADQELGDAPFLDR 0 8
NS1 26-40 ELGDAPFLDRLRRDQ 4 2
NS1 31-45 PFLDRLRRDQKSLRG 1 4
NS1 36-50 LRRDQKSLRGRGSTL 0 3
NS1 41-55 KSLRGRGSTLGLDIK 3 3
NS1 46-60 RGSTLGLDIKTATRA 1 5
NS1 51-65 GLDIKTATRAGKQIV 1 1
NS1 56-70 TATRAGKQIVERILK 4 3
NS1 61-75 GKQIVERILKEESDE 2 3
NS1 66-80 ERILKEESDEALKMT 6 4
NS1 71-85 EESDEALKMTMASVP 3 2
NS1 76-90 ALKMTMASVPASRYL 5 4
NS1 81-95 MASVPASRYLTDMTL 1 5
NS1 86-100 ASRYLTDMTLEEMSR 3 3
NS1 91-105 TDMTLEEMSRDWSML 7 3
NS1 96-110 EEMSRDWSMLIPKQK 3 2
NS1 101-115 DWSMLIPKQKVAGPL 6 12
NS1 106-120 IPKQKVAGPLCIRMD 5 23
NS1 111-125 VAGPLCIRMDQAIMD 9 5
NS1 116-130 CIRMDQAIMDKNIIL 3 3
NS1 121-135 QAIMDKNIILKANFS 2 5
NS1 126-140 KNIILKANFSVIFDR 6 1
NS1 131-145 KANFSVIFDRLETLI 2 4
NS1 136-150 VIFDRLETLILLRAF 5 8
NS1 141-155 LETLILLRAFTEEGA 5 5
NS1 146-160 LLRAFTEEGAIVGEI 12 2
NS1 151-165 TEEGAIVGEISPLPS 2 3
NS1 156-170 IVGEISPLPSLPGHT 7 6
NS1 161-175 SPLPSLPGHTAEDVK 7 2
NS1 166-180 LPGHTAEDVKNAVGV 3 2
NS1 171-185 AEDVKNAVGVLIGGL 4 6
NS1 176-190 NAVGVLIGGLEWNDN 3 4
NS1 181-195 LIGGLEWNDNTVRVS 7 3
NS1 186-200 EWNDNTVRVSETLQR 2 2
NS1 191-205 TVRVSETLQRFAWRS 6 1
NS1 196-210 ETLQRFAWRSSNENG 14 2
NS1 201-215 FAWRSSNENGRPPLT 11 3
NS1 206-220 SNENGRPPLTPKQKR 8 7
NS1 211-225 RPPLTPKQKREMAGT 3 11
NS1 216-230 PKQKREMAGTIRSEV 6 8
NS1 221-230 EMAGTIRSEV 2 10
NS2 1-15 MDPNTVSSFQDILLR 0 2
NS2 6-20 VSSFQDILLRMSKMQ 2 3
NS2 11-25 DILLRMSKMQLESSS 1 0
NS2 16-30 MSKMQLESSSEDLNG 1 1
NS2 21-35 LESSSEDLNGMITQF 2 0
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Peptide Sequence Elispota
NS2 26-40 EDLNGMITQFESLKL 8 5
NS2 31-45 MITQFESLKLYRDSL 10 6
NS2 36-50 ESLKLYRDSLGEAVM 5 3
NS2 41-55 YRDSLGEAVMRMGDL 3 5
NS2 46-60 GEAVMRMGDLHSLQN 1 4
NS2 51-65 RMGDLHSLQNRNEKW 0 3
NS2 56-70 HSLQNRNEKWREQLG 2 6
NS2 61-75 RNEKWREQLGQKFEE 4 2
NS2 66-80 REQLGQKFEEIRWLI 2 6
NS2 71-85 QKFEEIRWLIEEVRH 0 6
NS2 76-90 IRWLIEEVRHKLKIT 2 10
NS2 81-95 EEVRHKLKITENSFE 0 3
NS2 86-100 KLKITENSFEQITFM 4 4
NS2 91-105 ENSFEQITFMQALHL 11 61
NS2 96-110 QITFMQALHLLLEVE 2 5
NS2 101-115 QALHLLLEVEQEIRT 1 8
NS2 106-120 LLEVEQEIRTFSFQL 2 4
NS2 111-121 QEIRTFSFQLI 5 5
M1 1-15 MSFLTEVETYVLSII 2 5
M1 6-20 EVETYVLSIIPSGPL 2 6
M1 11-25 VLSIIPSGPLKAEIA 3 7
M1 16-30 PSGPLKAEIAQRLED 5 5
M1 21-35 KAEIAQRLEDVFAGK 1 13
M1 26-40 QRLEDVFAGKNTDLE 3 3
M1 31-45 VFAGKNTDLEVLMEW 4 2
M1 36-50 NTDLEVLMEWLKTRP 3 2
M1 41-55 VLMEWLKTRPILSPL 5 6
M1 46-60 LKTRPILSPLTKGIL 9 3
M1 51-65 ILSPLTKGILGFVFT 6 2
M1 56-70 TKGILGFVFTLTVPS 3 16
M1 61-75 GFVFTLTVPSERGLQ 7 4
M1 66-80 LTVPSERGLQRRRFV 3 3
M1 71-85 ERGLQRRRFVQNALN 1 3
M1 76-90 RRRFVQNALNGNGDP 3 4
M1 81-95 QNALNGNGDPNNMDK 6 3
M1 86-100 GNGDPNNMDKAVKLY 6 2
M1 91-105 NNMDKAVKLYRKLKR 1 2
M1 96-110 AVKLYRKLKREITFH 4 14
M1 101-115 RKLKREITFHGAKEI 4 6
M1 106-120 EITFHGAKEISLSYS 12 4
M1 111-125 GAKEISLSYSAGALA 2 2
M1 116-130 SLSYSAGALASCMGL 3 6
M1 121-135 AGALASCMGLIYNRM 7 6
M1 126-140 SCMGLIYNRMGAVTT 5 4
M1 131-145 IYNRMGAVTTEVAFG 2 10
M1 136-150 GAVTTEVAFGLVCAT 2 7
M1 141-155 EVAFGLVCATCEQIA 7 7
M1 146-160 LVCATCEQIADSQHR 4 4
M1 151-165 CEQIADSQHRSHRQM 4 16
M1 156-170 DSQHRSHRQMVTTTN 6 3
Peptide Sequence Elispota
M1 161-175 SHRQMVTTTNPLIRH 2 6
M1 166-180 VTTTNPLIRHENRMV 3 2
M1 171-185 PLIRHENRMVLASTT 1 2
M1 176-190 ENRMVLASTTAKAME 4 7
M1 181-195 LASTTAKAMEQMAGS 7 6
M1 186-200 AKAMEQMAGSSEQAA 4 2
M1 191-205 QMAGSSEQAAEAMEV 0 3
M1 196-210 SEQAAEAMEVASQAR 1 9
M1 201-215 EAMEVASQARQMVQA 12 32
M1 206-220 ASQARQMVQAMITIG 9 35
M1 211-225 QMVQAMITIGTHPSS 11 29
M1 216-230 MITIGTHPSSSAGLK 3 8
M1 221-230 THPSSSAGLKNDLLE 4 14
M1 226-240 SAGLKNDLLENLQAY 7 3
M1 231-245 NDLLENLQAYQKRMG 8 5
M1236-250 NLQAYQKRMGVQMQR 3 5
M1 241-252 QKRMGVQMQRFK 1 2
M2 1-15 MSFLTEVETPIRNEW 0 5
M2 6-20 EVETPIRNEWGCRCN 0 5
M2 11-25 IRNEWGCRCNGSSDP 1 4
M2 16-30 GCRCNGSSDPLTIAA 4 4
M2 21-35 GSSDPLTIAANIIGI 1 6
M2 26-40 LTIAANIIGILHLTL 0 4
M2 31-45 NIIGILHLTLWMLDR 1 5
M2 36-50 LHLTLWMLDRLFFKC 5 14
M2 41-55 WMLDRLFFKCIYRRF 10 5
M2 46-60 LFFKCIYRRFKYGLK 5 10
M2 51-65 IYRRFKYGLKGGPST 5 6
M2 56-70 KYGLKGGPSTEGVPK 3 3
M2 61-75 GGPSTEGVPKSMREE 2 3
M2 66-80 EGVPKSMREEYRKEQ 6 4
M2 71-85 SMREEYRKEQQSAVD 4 4
M2 76-90 YRKEQQSAVDTDDGH 6 8
M2 81-95 QSAVDTDDGHFVSIE 5 10
M2 86-97 TDDGHFVSIELE 8 10
a  Number of Elispots from 105 spleen cells, determined in two independent 
experiments. Peptides were screened on mice that had recovered from 
an x31 infection.  The regions containing the known Class I and Class II 
epitopes are indicated by shading and the peptides investigated further 
are in bold.  
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Supplemental Table 2 .PR8 Influenza virus peptides
Peptide Sequence Elispota
HA 1-15 MKANLLVLLSALAAA 0 0
HA 6-20 LVLLSALAAADADTI 0 0
HA 11-25 ALAAADADTICIGYH 1 1
HA 16-30 DADTICIGYHANNST 3 1
HA 21-35 CIGYHANNSTDTVDT 2 1
HA 26-40 ANNSTDTVDTVLEKN 4 2
HA 31-45 DTVDTVLEKNVTVTH 3 3
HA 36-50 VLEKNVTVTHSVNLL 6 4
HA 41-55 VTVTHSVNLLEDSHN 5 2
HA 46-60 SVNLLEDSHNGKLCR 1 1
HA 51-65 EDSHNGKLCRLKGIA 3 5
HA 56-70 GKLCRLKGIAPLQLG 2 1
HA 61-75 LKGIAPLQLGKCNIA 1 1
HA 66-80 PLQLGKCNIAGWLLG 0 0
HA 71-85 KCNIAGWLLGNPECD 2 2
HA 76-90 GWLLGNPECDPLLPV 13 6
HA 81-95 NPECDPLLPVRSWSY 4 1
HA 86-100 PLLPVRSWSYIVETP 6 3
HA 91-105 RSWSYIVETPNSENG 2 4
HA 96-110 IVETPNSENGICYPG 10 2
HA 101-115 NSENGICYPGDFIDY 7 1
HA 106-120 ICYPGDFIDYEELRE 3 3
HA 111-125 DFIDYEELREQLSSV 7 5
HA 116-130 EELREQLSSVSSFER 1 4
HA 121-135 QLSSVSSFERFEIFP 2 6
HA 126-140 SSFERFEIFPKESSW 3 7
HA 131-145 FEIFPKESSWPNHNT 4 1
HA 136-150 KESSWPNHNTNGVTA 5 2
HA 141-155 PNHNTNGVTAACSHE 3 4
HA 146-160 NGVTAACSHEGKSSF 2 1
HA 151-165 ACSHEGKSSFYRNLL 6 2
HA 156-170 GKSSFYRNLLWLTEK 6 3
HA 161-175 YRNLLWLTEKEGSYP 4 5
HA 166-180 WLTEKEGSYPKLKNS 3 4
HA 171-185 EGSYPKLKNSYVNKK 6 1
HA 176-190 KLKNSYVNKKGKEVL 4 0
HA 181-195 YVNKKGKEVLVLWGI 1 0
HA 186-200 GKEVLVLWGIHHPPN 1 1
HA 191-205 VLWGIHHPPNSKEQQ 1 1
HA 196-210 HHPPNSKEQQNIYQN 2 2
HA 201-215 SKEQQNIYQNENAYV 2 3
HA 206-220 NIYQNENAYVSVVTS 6 4
HA 211-225 ENAYVSVVTSNYNRR 3 5
HA 216-230 SVVTSNYNRRFTPEI 5 2
HA 221-235 NYNRRFTPEIAERPK 8 1
HA 226-240 FTPEIAERPKVRDQA 1 5
HA 231-245 AERPKVRDQAGRMNY 2 1
HA 236-250 VRDQAGRMNYYWTLL 4 3
HA 241-255 GRMNYYWTLLKPGDT 0 0
HA 246-260 YWTLLKPGDTIIFEA 1 0
HA 251-265 KPGDTIIFEANGNLI 0 0
Peptide Sequence Elispota
HA 256-270 IIFEANGNLIAPMYA 1 5
HA 261-275 NGNLIAPMYAFALSR 2 4
HA 266-280 APMYAFALSRGFGSG 1 3
HA 271-285 FALSRGFGSGIITSN 2 1
HA 276-290 GFGSGIITSNASMHE 3 5
HA 281-295 IITSNASMHECNTKC 4 1
HA 286-300 ASMHECNTKCQTPLG 3 7
HA 291-305 CNTKCQTPLGAINSS 8 5
HA 296-310 QTPLGAINSSLPYQN 6 1
HA 301-315 AINSSLPYQNIHPVT 0 2
HA 306-320 LPYQNIHPVTIGECP 0 2
HA 311-325 IHPVTIGECPKYVRS 0 0
HA 316-330 IGECPKYVRSAKLRM 0 0
HA 321-335 KYVRSAKLRMVTGLR 1 0
HA 326-340 AKLRMVTGLRNTPSI 2 0
HA 331-345 VTGLRNTPSIQSRGL 4 1
HA 336-350 NTPSIQSRGLFGAIA 8 3
HA 341-355 QSRGLFGAIAGFIEG 2 2
HA 346-360 FGAIAGFIEGGWTGM 4 5
HA 351-365 GFIEGGWTGMIDGWY 3 1
HA 356-370 GWTGMIDGWYGYHHQ 4 5
HA 361-375 IDGWYGYHHQNEQGS 2 4
HA 366-380 GYHHQNEQGSGYAAD 1 7
HA 371-385 NEQGSGYAADQKSTQ 3 6
HA 376-390 GYAADQKSTQNAING 2 3
HA 381-395 QKSTQNAINGITNKV 1 1
HA 386-400 NAINGITNKVNTVIE 3 1
HA 391-405 ITNKVNTVIEKMNIQ 8 2
HA 396-410 NTVIEKMNIQFTAVG 3 2
HA 401-415 KMNIQFTAVGKEFNK 1 1
HA 406-420 FTAVGKEFNKLEKRM 2 2
HA 411-425 KEFNKLEKRMENLNK 1 1
HA 416-430 LEKRMENLNKKVDDG 0 2
HA 421-435 ENLNKKVDDGFLDIW 0 1
HA 426-440 KVDDGFLDIWTYNAE 2 5
HA 431-445 FLDIWTYNAELLVLL 2 3
HA 436-450 TYNAELLVLLENERT 1 0
HA 441-455 LLVLLENERTLDFHD 2 0
HA 446-460 ENERTLDFHDSNVKN 2 0
HA 451-465 LDFHDSNVKNLYEKV 3 3
HA 456-470 SNVKNLYEKVKSQLK 8 4
HA 461-475 LYEKVKSQLKNNAKE 1 2
HA 466-480 IGNGCFEFYHKCDNE 4 1
HA 471-485 FEFYHKCDNECMESV 2 3
HA 476-490 KCDNECMESVRNGTY 3 1
HA 481-495 CMESVRNGTYDYPKY 3 3
HA 486-500 RNGTYDYPKYSEESK 2 1
HA 491-505 DYPKYSEESKLNREK 1 3
HA 496-510 SEESKLNREKVDGVK 1 1
HA 501-515 LNREKVDGVKLESMG 4 2
HA 506-520 VDGVKLESMGIYQIL 0 1
HA 511-525 LESMGIYQILAIYST 0 0
Un e v e n Di s t r i b U t i o n o f MHC Cl a s s  ii  ep i t o p e s  w i t H i n t H e in f l U e n z a vi r U s   Suppl. 10
Peptide Sequence Elispota
HA 516-530 IYQILAIYSTVASSL 2 1
HA 521-535 AIYSTVASSLVLLVS 2 4
HA 526-540 VASSLVLLVSLGAIS 0 0
HA 531-545 VLLVSLGAISFWMCS 0 0
HA 536-550 LGAISFWMCSNGSLQ 1 0
HA 541-554 FWMCSNGSLQCRIC 2 1
HA 546-555 NGSLQCRICI 0 3
NA 1-15 MNPNQKITTIGSICL 0 4
NA 6-20 KITTIGSICLVVGLI 0 0
NA 11-25 GSICLVVGLISLILQ 2 1
NA 16-30 VVGLISLILQIGNII 1 2
NA 21-35 SLILQIGNIISIWIS 8 4
NA 26-40 IGNIISIWISHSIQT 1 3
NA 31-45 SIWISHSIQTGSQNH 0 2
NA 36-50 HSIQTGSQNHTGICN 3 1
NA 41-55 GSQNHTGICNQNIIT 0 4
NA 46-60 TGICNQNIITYKNST 4 3
NA 51-65 QNIITYKNSTWVKDT 2 5
NA 56-70 YKNSTWVKDTTSVIL 4 4
NA 61-75 WVKDTTSVILTGNSS 3 1
NA 66-80 TSVILTGNSSLCPIR 8 3
NA 71-85 TGNSSLCPIRGWAIY 2 4
NA 76-90 LCPIRGWAIYSKDNS 6 1
NA 81-95 GWAIYSKDNSIRIGS 4 3
NA 86-100 IRIGSKGDVFVIREP 7 0
NA 91-105 KGDVFVIREPFISCS 2 0
NA 96-110 VIREPFISCSHLECR 3 0
NA 101-115 FISCSHLECRTFFLT 4 3
NA 106-120 HLECRTFFLTQGALL 2 1
NA 111-125 TFFLTQGALLNDKHS 0 4
NA 116-130 QGALLNDKHSNGTVK 1 1
NA 121-135 NDKHSNGTVKDRSPY 2 0
NA 126-140 NGTVKDRSPYRALMS 0 0
NA 131-145 DRSPYRALMSCPVGE 5 2
NA 136-150 RALMSCPVGEAPSPY 6 2
NA 141-155 CPVGEAPSPYNSRFE 5 1
NA 146-160 APSPYNSRFESVAWS 2 4
NA 151-165 NSRFESVAWSASACH 2 3
NA 156-170 SVAWSASACHDGMGW 3 2
NA 161-175 ASACHDGMGWLTIGI 9 5
NA 166-180 DGMGWLTIGISGPDN 5 4
NA 171-185 LTIGISGPDNGAVAV 2 1
NA 176-190 SGPDNGAVAVLKYNG 2 2
NA 181-195 GAVAVLKYNGIITET 2 3
NA 186-200 LKYNGIITETIKSWR 2 5
NA 191-205 IITETIKSWRKKILR 3 5
NA 196-210 IKSWRKKILRTQESE 1 3
NA 201-215 KKILRTQESECACVN 2 3
NA 206-220 TQESECACVNGSCFT 4 4
NA 211-225 CACVNGSCFTIMTDG 2 2
NA 216-230 GSCFTIMTDGPSDGL 2 3
Peptide Sequence Elispota
NA 221-235 IMTDGPSDGLASYKI 1 6
NA 226-240 PSDGLASYKIFKIEK 3 2
NA 231-245 ASYKIFKIEKGKVTK 0 0
NA 236-250 FKIEKGKVTKSIELN 2 0
NA 241-255 GKVTKSIELNAPNSH 2 1
NA 246-260 SIELNAPNSHYEECS 1 2
NA 251-265 APNSHYEECSCYPDT 1 5
NA 256-270 YEECSCYPDTGKVMC 5 0
NA 261-275 CYPDTGKVMCVCRDN 3 1
NA 266-280 GKVMCVCRDNWHGSN 1 2
NA 271-285 VCRDNWHGSNRPWVS 6 5
NA 276-290 WHGSNRPWVSFDQNL 4 3
NA 281-295 RPWVSFDQNLDYQIG 5 4
NA 286-300 FDQNLDYQIGYICSG 2 3
NA 291-305 DYQIGYICSGVFGDN 8 2
NA 296-310 YICSGVFGDNPRPED 0 2
NA 301-315 VFGDNPRPEDGTGSC 0 5
NA 306-320 PRPEDGTGSCGPVYV 0 3
NA 311-325 GTGSCGPVYVDGANG 0 3
NA 316-330 GPVYVDGANGVKGFS 1 1
NA 321-335 DGANGVKGFSYRYGN 2 2
NA 326-340 VKGFSYRYGNGVWIG 5 3
NA 331-345 YRYGNGVWIGRTKSH 1 4
NA 336-350 GVWIGRTKSHSSRHG 3 2
NA 341-355 RTKSHSSRHGFEMIW 4 2
NA 346-360 SSRHGFEMIWDPNGW 2 1
NA 351-365 FEMIWDPNGWTETDS 2 0
NA 356-370 DPNGWTETDSKFSVR 0 0
NA 361-375 TETDSKFSVRQDVVA 0 3
NA 366-380 KFSVRQDVVAMTDWS 0 2
NA 371-385 QDVVAMTDWSGYSGS 1 2
NA 376-390 MTDWSGYSGSFVQHP 0 1
NA 381-395 GYSGSFVQHPELTGL 0 2
NA 386-400 FVQHPELTGLDCMRP 4 1
NA 391-405 ELTGLDCMRPCFWVE 4 2
NA 396-410 DCMRPCFWVELIRGR 3 3
NA 401-415 CFWVELIRGRPKEKT 2 4
NA 406-420 LIRGRPKEKTIWTS 9 7
NA 411-425 PKEKT IWTSASSIS 3 2
NA 416-430 IWTSASSISFCGVN 3 1
NA 421-435 ASSISFCGVNSDTVD 0 0
NA 426-440 FCGVNSDTVDWSWPD 0 1
NA 431-444 SDTVDWSWPDGAELP 0 2
NA 436-450 WSWPDGAELPFSIDK 0 0
NA 441-450 GAELPFSIDK 1 0
a  Number of Elispots from 105 spleen cells, determined in two 
independent experiments.
Peptides were screened on mice that had recovered from an x31 
infection.  The regions containing the known Class I and Class 
II epitopes are indicated by shading and peptides investigated 
further are in bold.
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